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University of Connecticut, 2016 
 
Proteins are crucial in virtually all cell activities. The vast majority of proteins interact with 
other molecules to function properly. The investigation of biomolecular interactions calls for structural 
and thermodynamic information acquired by a variety of experimental techniques and analytical 
methods. This dissertation is mainly concentrated on two frequently used and powerful tools, Isothermal 
Titration Calorimetry (ITC) and Nuclear Magnetic Resonance (NMR) spectroscopy, to investigate 
protein interactions. p52 Shc, a well-studied cellular adaptor protein, is a positive regulator in the 
mitogen-activated protein kinases pathway. We have confirmed that Shc interacts with both, integrin 
tyrosine(s)-phosphorylated cytoplasmic tails and phosphotidylinositol lipids, through the same 
Phospho-Tyrosine Binding (PTB) domain. The binding to phosphorylated peptides is enthalpy driven 
and tighter, while Shc interactions with PtdIns are entropy driven and much weaker. Shc interactions 
with PtdIns and β3-derived peptides are only weakly competitive with partially overlapping bindings 
sites. We also observed thermodynamic indications for potential intramolecular interactions within Shc, 
which could be perturbed by the binding to the phosphorylated receptor. BTN3A1, an immunoglobulin 
superfamily member, was found recently to be critical in Vγ9Vδ2 T cell activation. We described a 
phosphoantigen prodrug approach with great potency in Vγ9Vδ2 T cell stimulation. Our NMR and ITC 
results revealed the intracellular binding of BTN3A1 to phosphoantigens. In addition, we have provided 
biophysical evidence indicating the involvement of membrane proximal region in phosphoantigen 
binding and potential structural changes within BTN3A1 intracellular region. By focusing on p52 Shc 
and BTN3A1, I hope to demonstrate how a combination of structural and thermodynamic knowledge 
can be utilized to answer many important questions in signaling transduction close to the cell membrane. 
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Chapter 1 ITC in Protein Interaction Study 
Principles of ITC 
In biology, the answers to many important questions about biomolecular interactions 
are closely related to a change in heat or enthalpy occurring during the process. ITC directly 
measures the heat change absorbed from the surroundings for an endothermic process or 
released to the surroundings for an exothermic process, which makes it an ideal technique to 
study biomolecular interactions. ITC is a powerful tool to study biomolecular interactions by 
depicting the complete thermodynamic profile including the binding affinity (Ka), the enthalpy 
(ΔH) and entropy (ΔS) changes in a single experiment for interaction of interest (1). 
ITC measures biochemical reactions at constant temperature. Modern ITC only 
requires low quantity of samples and is capable of studying interactions with a dissociation 
constant (Kd) in a range from nM to mM. Figure 1 is a schematic representation of NanoITC 
calorimeter from TA Instruments. In the assembly of ITC reside the sample and reference cells. 
When an ITC experiment is undergoing, the sample cell contains one of the reactant of the 
reaction of interest and the reference cell contains a solution which has a similar heat capacity 
of the buffer used for the sample in the sample cell. Prior to the start of the experiment, the 
other reactant in exactly the same buffer is loaded into the titration syringe. The syringe is then 
mounted onto the burette handle and inserted into the ITC instrument. During an experiment, 
the burette handle rotates and spins the syringe to ensure fast and adequate mixing of the two 
reactants. The stepwise injection of ITC is controlled by the software where the user can 
specify the settings for the experiment such as temperature, injection volume and stirring 
speed. 
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Figure 1. A schematic representation of Nano ITC from ta instruments. Figure taken from 
Nano Isothermal Titration Calorimeter (Nano ITC) Getting Started Guide, Revision A by TA 
Instruments. 
The mechanism of differential power compensation is utilized to achieve the high 
sensitivity and short response time (2). Currents are applied to both cells during the experiment 
to maintain them at constant temperature set by the user. The injection of one reactant in the 
injection syringe to the other reactant induces heat released to the surrounding environment 
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(an exothermic reaction) or absorbed from surrounding environment (an endothermic reaction). 
The heat change in the sample cell causes the change in the current applied to the sample 
cell resulting a voltage difference between the two cells. In this manner, the energetics of 
isothermal biochemical reactions is converted to electrical signals. 
Data Analysis of ITC 
The determination of the parameters of the thermodynamic profiles of the reaction can 
be derived from the basic equilibrium thermodynamics and Gibbs free energy equation (2, 3). 
To demonstrate of the analysis of ITC data, we consider the simplest scenario, in which a 
macromolecule (such as proteins and nucleic acids) binds to its ligand (such as small 
molecules) with 1:1 stoichiometry. The association of the macromolecule with the ligand gives 
us a reaction: 
 𝑀 + 𝐿 ⇌ 𝑀𝐿 (1) 
where M is the macromolecule, L is the ligand and ML is the macromolecule-ligand complex. 
For this reaction, the equilibrium association constant (Ka) is defined as: 
 𝐾𝑎 =
[𝑀𝐿]
[𝑀][𝐿]
=
1
𝐾𝑑
 (2) 
where [ML], [M], [L] are the concentrations of free ML, M and L, respectively, and Kd is the 
dissociation constant of the equilibrium. Due to the mass balance of the system, we have the 
following relations among the free, bound and total concentrations for M and L: 
 
[𝑀]𝐵 = [𝐿]𝐵 = [𝑀𝐿] (3) 
 
[𝑀]𝑇 = [𝑀] + [𝑀𝐿] (4) 
 
[𝐿]𝑇 = [𝐿] + [𝑀𝐿] (5) 
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where [M]B and [L]B are the concentrations of bound M and L, respectively, and [M]T and [L]T 
are the concentrations of total M and L, respectively. The Gibbs free energy can be derived 
from the following two equations: 
 Δ𝐺 = −𝑅𝑇𝑙𝑛𝐾𝑎 (6) 
 Δ𝐺 = Δ𝐻 − 𝑇Δ𝑆 (7) 
ITC directly measures the heat (qi) released or absorbed from the reaction triggered by 
the ith titration of L into M in the reaction cell. Meanwhile, qi is directly proportional to the 
characteristic enthalpy change (ΔH) of the reaction and increase in [L]B: 
 𝑞𝑖 = 𝑣 × Δ𝐻 × Δ[𝐿]𝑖 (8) 
where v is the volume of the reaction cell and ΔLi is the increase in [L]B thanks to the ith injection 
of L. In our simplest case where the macromolecule has only one binding site, the Equation (8) 
becomes: 
 𝑞𝑖 = 𝑣 × ΔΗ × [𝑀]𝑇 × ( 
𝐾𝑎[𝐿]𝑖
1 + 𝐾𝑎[𝐿]𝑖
−
𝐾𝑎[𝐿]𝑖−1
1 + 𝐾𝑎[𝐿]𝑖−1
 ) (9) 
where [L]i is the concentration of free ligand after the ith injection. However, the Equation (8) is 
still not in its implementable form and it needs to be rewritten in terms of the total ligand 
concentration. The total cumulative heat, Q, is directly proportional to [L]B (hence [ML] due to 
Equation (3)) as in: 
 𝑄 = 𝑣 × Δ𝐻 × ∑ Δ[𝐿]𝑖 = 𝑣 × Δ𝐻 × [𝐿]𝐵 = 𝑣 × Δ𝐻 × [𝑀𝐿] (10) 
which gives us the following equation: 
 
[𝑀𝐿]
[𝑀]𝑇
=
𝑄
𝑣 × Δ𝐻 × [𝑀]𝑇
 (11) 
 
From Equations (2) to (5), we also obtain: 
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[𝑀𝐿]
[𝑀]𝑇
=
𝐾𝑎[𝐿]
1 + 𝐾𝑎[𝐿]
 (12) 
 [𝑀]𝑇 = [𝑀𝐿] + [𝑀] = [𝑀𝐿] +
[𝑀𝐿]
𝐾𝑎[𝐿]
 (13) 
Thus, we have a quadratic equation for [ML]: 
 [𝑀𝐿]2 + [𝑀𝐿] (−[𝑀]𝑇 − [𝐿]𝑇 −
1
𝐾𝑎
) + [𝑀]𝑇[𝐿]𝑇 = 0 (14) 
The only real root for Equation (13) can solved and substituted in to Equations (5), (10) and 
(11). Eventually, we establish the implementable form to determine Ka, ΔH from the non-linear 
least-squares analysis of the dependent, Q, versus the known independent variable, usually 
[L]T/[M]T. The precise relation is: 
 𝑄 =
(1 + [𝑀]𝐾𝑎 + 𝐾𝑎[𝐿]𝑇) − [(1 + [𝑀]𝐾𝑎 + 𝐾𝑎[𝐿]𝑇)
2 − 4[𝑀]𝐾𝑎
2[𝐿]𝑇]
1/2
2𝐾𝑎
𝑣 × Δ𝐻
 (15) 
Figure 2 demonstrates the parameters calculation from the data acquired by ITC. The 
upper panel shows the raw data collected in an ITC experiment. Each peak is the heat change 
induced by an injection. The peaks pointing different directions (up or down) indicates the 
reaction being endothermic or exothermic. The lower panel represents the integration of the 
row data with the fitted curve for an exothermic protein-ligand interaction with 1:1 stoichiometry. 
Each data point on the plot of the lower panel is calculated from the area under peak for the 
corresponding peak in the row data. On the X-axis, the cumulative total ligand-protein ratios 
are calculated after each injection. 
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Figure 2. An example of itc raw data and processed data with a fitted independent model 
with 1:1 stoichiometry 
After the fitting, the important thermodynamic parameters are reflected on the sigmoidal 
curve (Figure 2). The distance between the two horizontal asymptotes of the curve represents 
the enthalpy change, ΔH, of the reaction. The stoichiometry of the reaction is obtained by 
determining where the midpoint is on the X-axis for the sigmoidal curve. The slope at this point 
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specifies the binding affinity, Ka, of the reaction. In addition, Equations (6) and (7) enable us to 
obtain the Gibbs free energy change, ΔG, and entropy change, ΔS, for the reaction of interest. 
Practical Considerations in an ITC Experiment 
ITC is popular in biophysical studies due to its simplicity and capability in determining 
a complete thermodynamic profile for the interaction of interest in short time (4). ITC 
instruments directly measure the energy associated with a chemical reaction in a stepwise 
fashion (1). The reaction cell contains one of the reactants, usually macromolecules such as 
proteins and nucleic acids. The other reactant of the reaction, usually with better stability and 
solubility at higher concentrations, such as small molecules, is loaded into the injection syringe 
and its injection is controlled by the ITC software. 
ITC is a highly sensitive technique to study biochemical reactions and it is easy to use. 
ITC experiments do not need any special modifications for the reactants and can be done 
using spectroscopically silent samples in a wide range biologically relevant conditions (such 
as pH, buffer and temperature). However, there are precautions a researcher needs to pay 
attention to in order to obtain the optimal results. 
For simplicity, we focus the association of a protein with its ligand of a small molecule 
with 1:1 stoichiometry (Table 1). An optimal binding curve from ITC should contain the two 
“platform” phases in the beginning and in the end of the curve while the transition phase is not 
too steep or flat to obtain an accurate estimate of the slope at the midpoint as shown in Figure 
3A. 
Kd (μM) ΔH (kJ/mol) TΔS (kJ/mol) stoichiometry 
1 50 15.75 1 
Table 1. Thermodynamic parameters for the simulated reaction 
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Figure 3. Simulated itc data to find the optimal concentrations for the reactants  
ITC is able to study biochemical reactions with a Kd in a range from nanomolar to 
millimolar. However, there are still limitations. We can determine if a reaction is suitable for 
ITC based on a parameter known as: 
 𝑐 = 𝐾𝑎 × [𝑀] (16) 
where Ka is the reciprocal of Kd and [M] is the concentration of macromolecule sample. An 
initial value of Kd can be obtained from other techniques or a test ITC run in order to calculate 
the value for c as in Equation 16. Modern ITC instruments are capable of directly measure 
reactions with 10 < c < 1000 (Table 2). A c value lower than 10 gives a transition too flat to 
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determine ΔH (Figure 3D). On the other hand, a c value greater than 1000 gives a transition 
too steep, which leaves few points to accurately determine the slope at the midpoint (Figure 
3E). 
Experiment [L] (μM) [M] (μM) c [L]/[M] Comment 
A 150 25 25 6 Optimal 
B 300 25 25 12 Saturated too fast 
C 75 25 25 3 Saturation not achieved 
D 15 2.5 2.5 6 c < 10 
E 7500 1250 1250 6 c > 1000 
Table 2. Concentrations used to generated simulated ITC data in Figure 3 
In order to achieve the optimal binding curve, the reactant is usually 5-10 times more 
concentrated than the other reactant in the sample cell (Figure 3, Table 2). Thus it is 
reasonable to have the reactant, which has better solubility and stability under the experiment 
condition, in the injection syringe. In case of our protein-ligand interaction example, it is a 
common practice to prepare the ligand of small molecule at a higher concentration. The exact 
ratio can be determined in simulation based on the volumes of the injection syringe and the 
sample cell of a specific ITC model available. 
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Chapter 2 NMR spectroscopy in Protein Interaction Study 
Overview of NMR Spectroscopy 
In biology, in order to understand how macromolecules (such as proteins and nucleic 
acids) function, related structural information is essential. ITC is popular in biophysical studies 
due to its simplicity and capability in determining a complete thermodynamic profile for 
interaction of interest in short time (4). NMR spectroscopy, on the other hand, focuses on 
structural information at the atomic level and is particularly valuable in protein dynamics studies. 
Along with X-ray crystallography, NMR spectroscopy has become one of the two primary 
techniques to solve three-dimensional structures of macromolecules including protein and 
nucleic acids. In addition, it is also widely used to reveal the structural details of biomolecular 
binding events such as protein-protein and protein-ligand interactions (5). Unlike X-ray 
crystallography, NMR can monitor biomolecular interactions in solution at a near-physiological 
condition. 
Over the past few decades, the range of biological system suitable for NMR has been 
remarkably expanded by the improvement in instrumentation, application of multidimensional 
techniques and other methodological advances (6-8). NMR has been employed successfully 
in structural determination of large-sized proteins (9) and membrane proteins (10). In the 
dissertation, we mainly utilized two-dimensional NMR experiments, especially 1H-15N HSQC, 
to study a variety of protein interactions and protein conformational changes upon ligand 
binding. 
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Principles of NMR Spectroscopy 
The fundamental principle of NMR spectroscopy comes from the behavior of nuclei in 
an external magnetic field. In the scope of our discussion here, we will focus on spin-1/2 nuclei 
(including 1H, 13C and 15N). When an external magnetic field is applied to the nuclei, the nuclei 
are distributed into higher and lower spin energy states. As described by the Boltzmann 
distribution, there are only slightly more nuclei at lower energy state than higher energy state. 
The energy difference between the two states, ΔE, is proportional to the strength of the external 
magnetic field: 
 Δ𝐸 =
𝜇𝐵0
𝐼
 (1) 
where µ is the magnetic moment of the nucleus, B0 is the strength of applied external magnetic 
field and I is the spin number of the nucleus (I = ½ for spin-1/2 nuclei). The magnetic moment, 
µ, is positively related to the gyromagnetic ratio, γ, of the nucleus: 
 𝜇 =
𝛾𝐼ℎ
2𝜋
 (2) 
where h is Planck constant. 
 
Figure 4. Spin-1/2 nuclei in an external magnetic field. E represents the energy difference 
between the two states and B0 is the strength of applied external magnetic field. Figure taken 
from https://www2.chemistry.msu.edu/faculty/reusch/virttxtjml/spectrpy/nmr/nmr1.htm. 
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When a nucleus is irradiated with radio frequency (RF) energy corresponding exactly 
to the difference between the two energy states, nuclei at lower energy state absorb the energy 
and are excited to the higher energy state resulting in NMR signals. The process of nuclei in 
excitation return to the lower energy state is called relaxation in NMR. Relaxation also 
describes how NMR signals deteriorate with time. The rate of relaxation can be used to define 
how fast NMR signals become gradually weaker and broader and is vital in NMR spectroscopy. 
There are two major relaxation processes: spin-lattice relaxation and spin-spin 
relaxation. The spin-lattice relaxation is a process in which the nuclei emits energy to the 
surrounding environment. T1 is often used to describe how long this process takes place and 
is also the decay constant for the recovery of the longitudinal component (parallel to the 
direction of B0 in Figure 5A) of the nuclear spin magnetization in excitation to the equilibrium 
state. The spin-spin relaxation, on the other hand, is a process in which a nucleus interacts 
with neighboring nuclei resulting in a decaying transverse nuclear spin magnetization due to 
decoherence. The over-population of the excited state does not change in the spin-spin, or T2, 
relaxation but the life time of the NMR signal from the transverse nuclear magnetization 
(perpendicular to the direction of B0 in Figure 5B) becomes shorter. T1 relaxation is responsible 
for the weakening and T2 is accountable for the broadening in NMR signals. 
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Figure 5. T1 (spin-lattice) and T2 (spin-spin) relaxation (from blue to red). The Z-axis 
represent the direction of B0. Figure modified from http://www-mrsrl.stanford.edu/~brian/bloch/. 
Chemical Shifts in Protein NMR 
The magnetic field at the nucleus is not equal to the applied external magnetic field due 
to the nuclear shielding phenomena in which the electrons circulating around a nucleus creates 
a secondary induced magnetic field. The induced magnetic field can oppose or align with the 
external magnetic field causing a shift in the resonant frequency of a nucleus in a magnetic 
field. After standardized by a reference, the chemical shift is defined as the relative resonant 
frequency of a nucleus to the reference, which is independent of the strength of the external 
magnetic field. In chemistry, chemical shifts are particularly helpful for structural determination 
of small molecules. 
In protein NMR, the backbone chemical shift assignments of 13Cα, 13Cβ, 13C’, 15N, 1Hα 
and 1HN, as the first step in NMR structure determination process, can often be carried out 
rapidly using moderate amount of sample. NMR chemical shifts, which are highly sensitive to 
local structure, provides us with a broad range of structural factors including secondary 
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structure, backbone and sidechain conformations and hydrogen bonding (11, 12). Thus, the 
structural information encoded in chemical shift values should not be overlooked. In addition, 
assorted protein dynamics studies require the prerequisite assignment of the chemical shifts 
of backbone atoms. Notably, the exploration of the structure-chemical shift relationship has 
been an active area and advancing rapidly. Direct utilization of backbone chemical shifts has 
been shown to considerably improve the accuracy of the protein structures predicted from 
homology/de novo modeling (13, 14). The capability of predicting high-quality protein 
structures based on sequence homology and experimental NMR backbone chemical shift data 
may represent a new direction for high-throughput NMR structure determination. 
1H-15N HSQC 2D Experiments 
Among a variety of 2D heteronuclear NMR experiments (such HSQC and HMQC), 1H-
15N HSQC is one of the most frequently used experiments in protein NMR (15). 1H-15N HSQC 
experiments require 15N protein samples which are easy to produce and inexpensive compared 
to 13C labeled samples. Due to its better sensitivity, 1H-15N HSQC can be acquired in a short 
period of time compared other multidimensional NMR experiments. 1H-15N HSQC correlates 
the chemical shifts of the amide protons with the covalently bound 15N amide nitrogens. In a 
1H-15N HSQC spectrum, each peak represents a bonded amide N-H pair with the 
corresponding coordinates of the chemical shifts of the 1H and 15N. 1H-15N HSQC spectra can 
be considered as the “finger-print” of the protein and are often collected first in the structural 
determination process. The perturbation of chemical shifts in 1H-15N HSQC spectra can serve 
as indicators for protein interactions. With the assignment of the spectrum, the perturbations 
can be mapped upon the protein structure hence reveal the binding sites on the protein for its 
ligand.  
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Chapter 3 p52 Shc in Signaling 
Shc Family 
Shc was one of the first characterized cellular adaptor proteins and a key node in the 
activation of MAPK signaling in response to growth factors, cytokines, antigens, integrin 
activation and mechanical force (16-18). By complexing with a wide range of membrane 
receptors, the Shc family stands as a first point of signaling network convergence in cell by 
transducing signals from the cell surface to DNA in the nucleus. The Shc family has significant 
physiological impact on animal development and maintenance (16). Furthermore, Shc has 
been implicated to be crucial in cancers including prostate (19) and breast cancer (20-22), and 
many other diseases (16). In human, the p52 isoform of Shc is ubiquitously expressed but also 
highly regulated. Given its pivotal role in cell regulation, vast in vivo and in vitro studies have 
been conducted in last two decades to decode the molecular mechanism of Shc in signaling. 
However, a number of new findings lend strong evidence to notion that Shc plays a versatile 
role in signal transduction including its inhibitory function in the MAPK signaling pathway (23) 
and its positive regulation in the PI3K/AKT pathway (21, 24).  
All members in the Shc family share a PTB-CH1-SH2 core architecture (Figure 6) and 
are only distinguished by the difference in the length of their N-termini (16). In addition to its C-
terminal SH2 domain, which is capable of binding tyrosine-phosphorylated targets, the N-
terminal PTB domain was later characterized as a novel type of protein motif, which also binds 
tyrosine-phosphorylated targets. Nonetheless, the two independent pTyr-docking domains, 
PTB and SH2, recognize pTyr-containing sequences in two distinct manners. In case of the 
PTB domain, the classical pTyr-binding site defines its specificity by selectively recognizing 
the residues N-terminal to the pTyr residue (25), especially the sequence Φ-X-Asn-Pro-X-pTyr 
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(Φ represents a hydrophobic residue); however, the specificity of SH2 is primarily determined 
by residues C-terminal to the pTyr residue and prefers the sequence pTyr-Φ-X-Ile/Leu/Met 
(26). Between the PTB and SH2 lies the highly flexible proline-rich CH1 region, which, once 
phosphorylated at Y239/240 (27, 28) and Y317 (29, 30), offers the recognition motifs to the 
downstream partner Grb2 to activate the MAPK pathway. 
 
Figure 6. The protein architecture of p52 Shc. The yellow circles represent the tyrosines in 
the CH1 region which undergo phosphorylation during the activation of Shc. 
Shc in MAPK Pathway 
The canonical view of Shc in the MAPK pathway is in linking stimulated receptors to 
the activation of the downstream MAPK pathway (17). Generally, activated and tyrosine-
phosphorylated receptors recruit Shc through the PTB or SH2 domain of Shc. Interestingly, 
the PTB domain, not SH2, is predominantly chosen by membrane receptors. Therefore so far 
most in vivo and in vitro studies on Shc have focused on the PTB domain. Recruitment of Shc 
to the activated receptors leads to phosphorylation in the CH1 region of Shc at Y239/240 and Y317 
(27, 29). The phosphorylated tyrosine residues form two consensus binding motifs to 
downstream adaptor protein Grb2. The formation of Shc-Grb2 complex leads to the activation 
of Ras/MAPK and results in the phosphorylation of the terminal kinase Erk by Mek in the MAPK 
pathway (16). In summary, traditionally defined as a positive mediator in pTyr-based signaling 
pathways, Shc links stimulated membrane receptors (via PTB or SH2) to downstream signaling 
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pathways (via CH1) activating Ras/MAPK. Though remarkable progress has been achieved in 
our knowledge of Shc, many intriguing studies have led to a perception that Shc functions in 
more ways than its role as a positive regulator in the MAPK pathway.  
Shc in PI3K/AKT Pathway 
By using a combination of in vivo and in vitro methods, Suen and co-workers 
demonstrated that the PTB domain of Shc exhibits direct binding to the N-terminal lobe of Erk 
kinase in non-stimulated cells (23). This interaction was suggested to have inhibitory effects 
on Erk’s activity by restraining its nuclear translocation and impeding Erk-dependent gene 
transcription. The binary Shc-Erk complex is disrupted once the CH1 region of Shc is tyrosine-
phosphorylated resulting in a potential conformational change within Shc. The release of Erk 
from the Shc-Erk complex makes Erk susceptible for activation. Those exciting findings 
strongly indicate a new inhibitory role of Shc in the MAPK pathway. Combined with its orthodox 
positive regulatory function, a dual role of Shc in MAPK is suggested: in non-stimulated cells, 
Shc suppresses the activation of MAPK by coupling with Erk and restricting its kinase activity; 
in the presence of extracellular stimuli, Shc is recruited by various receptors and 
phosphorylated in the CH1 region, ultimately leading to the activation of MAPK. Integrins, a 
major class of transmembrane receptors which mediate cell-cell and cell-extracellular matrix 
interactions (31), are among the broad range of receptors recruiting Shc via the PTB domain 
(32, 33). Previously, we have identified a classical binding site and a novel binding site on PTB 
for β3CT (34). Surprisingly, the suggested binding site on PTB for Erk overlaps with the novel 
binding site for pY747 of β3CT (Figure 7). It would be very intriguing to investigate how Erk and 
β3CT compete over the same binding site on the Shc PTB domain. 
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Figure 7. Illustration of Erk and β3CT competing over the same binding site on Shc PTB. 
The structure of the PTB domain (light yellow) in complex with bi-β3 (green) is generated from 
PDB entry 2L1C. The amino acids suggested to directly bind Erk are colored in blue (23). The 
region resides in the long loop which contributes to form the novel binding site for pY747 in β3CT. 
As Shc has been defined as a major signaling axis that activates the MAPK signaling 
pathways, several studies have shown its importance in the PI3K/AKT pathway (21, 24). The 
PI3K/AKT pathway makes significant contributions to many aspects of cell growth and survival 
(35). Class 1A PI3Ks (hereafter referred to as PI3Ks) comprise a regulatory/inhibitory subunit 
p85 and a catalytic subunit p110. When activated, PI3Ks, via its p85 subunit, are recruited to 
the plasma membrane by various receptors and produce phosphatidylinositol-(3,4,5)-
trisphosphate (PIP3) as a secondary messenger (35). AKT has been identified as the major 
positive downstream mediator of the PI3K signaling pathway. Gu and co-workers performed 
in vitro studies demonstrating Shc’s positive function in the activation of PI3K/AKT pathway 
(24). They found that by forming the complex of Shc-Grb2-Gab2, CH1-phosphoyrlated Shc, as 
a part of the complex, is linked to the p85 subunit of PI3K and eventually promotes the 
activation of downstream AKT. This new mechanism of Shc was believed to be crucial in the 
activation of the PI3K/AKT mediated by receptors lacking direct binding sites for the p85 
subunit of PI3K. 14-3-3 proteins, a class of ubiquitously expressed phosphoserine/threonine 
binding modules and known to bind a wide range of diverse signaling proteins, serve as 
positive regulators of Akt downstream signaling (36). Recently, the Tyr179 of 14-3-3 was found 
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to be phosphorylated in a cytokine-dependent manner and a direct interaction occurs between 
the SH2 domain of Shc and pY179 of 14-3-3ζ (37). Moreover, over-expression of the ζ isoform 
of the 14-3-3 protein family was found to be associated with increased AKT phosphorylation in 
human breast tumors (38). Later on, by employing transgenic mice expressing Shc with non-
functional SH2 domain, Ursini-Siegel and co-workers showed the SH2-dependent Shc 
signaling in the activation of PI3K/AKT is crucial for breast tumor outgrowth and survival (21). 
Thus, it is highly likely that Shc, via its CH1 and/or SH2, plays a significant role in the PI3K/AKT 
pathway.  
We have used a phosphopeptide encompassing pY179 of 14-3-3ζ (p-1433ζ: 
174FSVFY(pY)EILNSPEK186) in our ITC studies to confirm the presence of a direct interaction 
between isolated Shc SH2 domain and pY179-14-3-3ζ. The thermodynamic parameters of the 
interactions revealed a binding affinity in the low μM range and an enthalpy and entropy-
favorable process (Figure 8 and Table 3). 
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Figure 8. ITC results showing a direct interaction between Shc SH2 domain and p-1433ζ 
phosphopeptide at 37 °C 
Kd (µM) ΔH (kJ/mol) -TΔS (kJ/mol) ΔG (kJ/mol) 
6.28 ± 0.209 -6.45 ± 0.531 23.5 ± 4.56 -30.0 ± 4.03 
Table 3. Summary of the thermodynamic data for Shc SH2 interaction with p-1433ζ 
phosphopeptide at 37 °C 
In summary, as a convergence point for many signaling pathways, Shc has been 
believed to fulfill an up-regulatory function in the MAPK pathway. A growing number of 
independent studies have suggested the biological significance of Shc is not limited to this. In 
the MAPK pathway, Shc may also act to prohibit undesirable activation in the non-stimulated 
cell by complexing with Erk kinase (23). Outside the MAPK pathway, Shc seems to be crucial 
in the up-regulation of the PI3K/AKT pathway involving membrane receptors lacking a binding 
site for p85 subunit of PI3K (21, 24). Increasing studies have shown the necessity to better 
understand the diversity of Shc’s functionality in signaling. 
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Chapter 4 Phospho-Tyrosine(s) versus Phosphatidylinositol Binding in Shc 
Mediated Integrin Signaling 
Based on Lin, X. and Vinogradova, O., 2015. Phospho-Tyrosine (s) vs. Phosphatidylinositol 
Binding in Shc Mediated Integrin Signaling. American journal of molecular biology, 5(2), p.17.  
Introduction 
Integrin mediated signaling events control numerous developmental, physiological and 
pathological processes in multicellular organisms. Although significant progress has been 
achieved in the understanding of integrin activation (39, 40), the early intracellular events 
following the integrin mediated extracellular matrix engagement are not well characterized 
structurally. To illuminate the potential mechanisms of integrin selectivity in the recognition of 
proximal effectors at different stages of cell spreading, we have studied the effect of 
phosphorylation on the conformation, membrane insertion, and target binding capability of the 
cytoplasmic tail of the major platelet integrin αIIbβ3 (41, 42). Here we extend this investigation 
by presenting our new work on deciphering the role that PtdIns lipids might share with 
phosphotyrosine(s) in integrin signaling. 
Amongst the number of potential chemical modifications correlated with the activated 
state of integrin receptor, it is the tyrosine(s) phosphorylation of the cytoplasmic tail that has 
been proven crucial for the outside-in signaling events (43-47). Shc p52 isoform, more 
specifically, its PTB domain, has been identified as the primary signaling partner for the 
tyrosine(s) phosphorylated β3CT (47, 48).  This cytoplasmic adaptor protein, known to mediate 
MAPK signaling pathway (49), needs to be localized at the cytosolic face of the plasma 
membrane in order to be readily recruited by a number of different receptors (50). Two of Shc’s 
three distinct domains, PTB and SH2, have the potential to bind phospholipids and, thus, might 
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assist Shc translocation to the lipid bilayer (51, 52). Though only the PTB, and not the SH2 
domain, is shown to interact with specific PtdIns (53). The purpose of the work presented here 
is to compare molecular details of the interaction between Shc and integrin to the binding mode 
between Shc and phospholipids. 
Since their discovery about two decades ago, PTB domains have been identified and 
structurally characterized within numerous multi-domain proteins. The ways they interact with 
their targets are strikingly versatile. The phosphorylated tyrosine is not always required for the 
high affinity interactions, and, in some cases, the binding motif might not even contain the 
tyrosine residue at all (54). PTB domains in general are also famous for the significant variance 
in their ligand binding affinities, ranging from 0.1 to 100 μM  (55). Shc PTB domain in particular 
exhibits a wide range of affinities to various tyrosine-phosphorylated binding partners. The 
tightest interaction, with a Kd of 0.19 µM, was measured by ITC for the nerve growth factor 
receptor TrkA derived peptide (56), correcting the originally over-estimated Kd value of 53 nM 
(by Scatchard analysis of Surface Plasmon Resonance data) (57). Upon the structure 
determination of Shc PTB in complex with a β3 integrin derived bi-phosphorylated peptide, bi-
β3 (41), we have found that the C-terminal phosphotyrosine (pY759) of β3CT occupies the 
classical PTB binding pocket. The other phosphotyrosine (pY747) containing motif fits nicely 
into the grove formed between the second helix and the unusually long flexible loop (~24 
residues) connecting the second beta strand with the second helix in PTB fold. In this 
interaction, a negatively charged phosphate group of pY747 forms a salt-bridge with a positively 
charged side chain of Shc R104. This second binding site is in close proximity to the Shc residue 
R112, which is situated at the beginning of the PTB domain second beta strand. This R112, along 
with two lysines, K116 and K139, which also contain positively charged side chains, has been 
proposed earlier to mediate Shc PTB-phospholipids interaction (58). In addition, Zhou and co-
workers have originally found that Shc PTB domain has higher specificities to acidic PtdIns, 
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particulalry PtdIns(4)P1 and PtdIns(4,5)P2 (Figure 9), over the other lipids that they have tested 
(53). Furthermore, the binding of the full length Shc, enclosing the SH2 domain, to Ins(1,4,5)P3 
(Figure 9), representing the polar head group of PtdIns(4,5)P2, has been reported to be much 
tighter than the binding of the isolated Shc PTB domain alone to PtdIns(4,5)P2 (59). Therefore, 
in order to investigate whether β3 integrin/phospholipids binding sites on Shc PTB surface 
indeed overlap, what the thermodynamic profiles of these interactions are, and how β3CT 
derived phosphopeptides might affect Shc’s ability to localize itself to the lipid bilayer we have 
initiated a through biophysical characterization of the above system. Here we present our data, 
acquired by ITC and NMR experiments, which allowed us to visualize PtdIns mediated Shc 
association with the lipid bilayer and how tyrosine(s)-phosphorylated integrin cytoplasmic tail 
could later replace PtdIns from their binding site on Shc surface. Out data also suggests that 
the interaction between the cytoplasmic tails of activated integrin receptors and Shc may result 
in the rearrangement/separation of Shc internal domains. 
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Figure 9. Structures of PtdIns molecules used in the study 
Shc Interaction with Phosphatidylinositols Tested Using Ins(1,4,5)P3 
We started our investigation by studying Shc binding to Ins (1,4,5)P3 using ITC. We 
were greatly surprised that we were not able to reproduce the data reported by George and 
co-workers, who have reported a tight dissociation constant (Kd of 0.7 µM) for the full length 
Shc (59). No binding was found under any conditions tested (to have a better control on all 
possible variables, we have purchased Ins (1,4,5)P3 from the same supplier (Cayman Chemical) 
as reported in the paper. The conditions we tested include: i) Shc PTB domain at 12°C and 
25°C in several different buffers (including exactly the same as the one described by George, 
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which is 50 mM Tris, pH 8.0, 200 mM NaCl, 1 mM Dithiothreitol); ii) Shc full length at 12°C 
and 25°C; and iii) Shc SH2 domain at 12°C and 25°C (typical raw titration data is shown as 
an example in the Figure 10a-c). In the attempt to interpret our negative findings, we 
hypothesized that the heat of the reaction was too small, actually below the detection range 
of our Nano ITC calorimeter. Thus, we turned to NMR as the method of choice due to its 
endogenous ability to capture the interactions with minimal or no enthalpy changes. In this 
case, we performed 15N-HSQC chemical shifts mapping experiments by titrating the 
unlabeled Ins(1,4,5)P3 into the 15N-labled Shc PTB domain. Under the conditions tested (see 
Materials and Methods for details), we only observed minimal chemical shift perturbations 
for the handful of residues in the 15N-HSQC spectra even at the maximum of lipid to protein 
ratio (15 to 1, Figure 10d). Uncertain about these findings, we decided to choose different 
lipid mimetics for further investigation. 
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Figure 10. ITC and NMR studies on the interaction of Shc PTB domain and Ins(1,4,5)P3. (a) 
Ins(1,4,5)P3 does not show to bind to Shc PTB domain at 25 °C in ITC. (b) Ins(1,4,5)P3 does not 
show to bind to full length Shc at 25 °C in ITC. (c) Ins(1,4,5)P3 does not show to bind to SH2 
domain at 25 °C in ITC. (d) 15N-HSQC titration of PTB domain by Ins(1,4,5)P3. The effect from 
Ins(1,4,5)P3 only show up at a high PTB-to-Ins(1,4,5)P3 ratio (1:15) and is less pronounced 
compared to PtdIns(4,5)P2. 
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Shc Interaction with Phosphatidylinositols Analysed by ITC Using PtdIns(4)P1 
and PtdIns(4,5)P2 
With minimal success observing Shc interaction with Ins(1,4,5)P3, representing 
exclusively the polar head-groups of phosphatidylinositols, we wondered whether the aliphatic 
chains of the lipids were necessary for the measurability of the binding by ITC and NMR. Long 
lipid chains are not exactly soluble in aqueous solution. Thus, to perform the binding studies 
described below, we restricted the length of aliphatic chains to six carbons in dihexanoyl, or 
eight in dioctonoyl phosphatidylinositol derivatives and concentrated on PTB domain of Shc, 
previously shown to interact specifically with PtdIns(4)P1 and PtdIns(4,5)P2 (53). Binding affinities 
for the apo PTB domain, originally examined in the unilamellar liposomes centrifugation assay, 
were reported to be 52 μM for PtdIns(4)P1 and 140 μM for PtdIns(4,5)P2. Binding affinity of the 
PTB domain complexed with TrkA peptide was reported to be even weaker, with a Kd of roughly 
450 μM for both lipids. 
First, we employed ITC to determine the binding affinities of the PTB domain to three 
different phosphatidylinositol containing soluble probes (see the Materials and Methods 
section for details). We measured a Kd of 95 µM and 125 µM for PtdIns(4)P1 and PtdIns(4,5)P2 
respectively (titration curves and isotherms are presented in Figure 11a and Figure 11b). ITC 
was not able to detect the binding PtdIns(5)P1 (titration curve is shown Figure 12), thus 
confirming the specificity of interaction reported by Zhou and coworkers. The ITC 
measurements demonstrated similar binding affinity for PtdIns(4,5)P2 as compared to the affinity 
previously determined by centrifugation assay data analysis, though PtdIns(4)P1 appeared to 
bind about two times weaker than reported before (53). Small amounts of heat are consumed 
upon binding (in addition to the relatively large heat of solvation), demonstrating endothermic 
interactions at 25°C that are driven predominantly by entropy. Considering these data, it is not 
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entirely surprising that we were only able to observe minimal Shc PTB binding with Ins(1,4,5)P3 
alone in ITC. The complete thermodynamic analysis of the above interactions is presented in 
the Table 4. 
 
Figure 11. ITC and NMR studies on the interaction of Shc PTB domain and PtdIns. (a) 
PtdIns(4)P1 and (b) PtdIns(4,5)P2 binding to Shc PTB domain at 25 °C. 
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Figure 12. PtdIns(5)P1 does not show to bind to Shc PTB domain at 25 °C in ITC 
Ligand Kd (µM) ΔH (kJ/mol) -TΔS (kJ/mol) ΔG (kJ/mol) 
PtdIns(4)P1 95.00 1.51 -24.46 -22.95 
PtdIns(4,5)P2 125.1 1.94 -24.21 -22.27 
PtdIns(5)P1 No binding 
Table 4. ITC data for Shc PTB domain binding to PtdIns at 25°C 
PtdIns Binding Sites on Apo Shc PTB Surface Partially Overlap with Integrin 
Binding Sites 
To find out the molecular details of these weak Shc-PtdIns interactions, we next 
employed NMR and performed 15N-HSQC chemical shifts mapping experiments which are 
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especially useful to define weak binding (60). Two non-labeled PtdIns derivatives, PtdIns(4)P1 
and PtdIns(4,5)P2, demonstrated to interact with Shc PTB by ITC experiments, were titrated into 
the samples containing 15N-labeled apo PTB domain. Chemical shift perturbations, associated 
with the probes binding, were monitored. Overall, the observed shifts in Shc PTB resonance 
frequencies were small. However, they were concentration dependent, reproducible, and 
similar among the two PtdIns tested. Furthermore, the same residues were affected as the 
ones in Ins(1,4,5)P3 titration described above (Figure 10d), but the shifts were more pronounced 
in case of PtdIns(4,5)P2, even at 5 to 1 lipid to protein ratio as compared of 15 to 1 ratio for 
Ins(1,4,5)P3. The close-ups of 15N-HSQC spectra of PTB in the presence of PtdIns(4,5)P2, 
exemplifying the most shifted resonances, are shown in Figure 13. These chemical shifts 
perturbations occur at three major binding regions. The first one, represented by the residues 
Q148, S149 and A168, overlaps with the classical phospho-tyrosine binding pocket of the protein-
peptide binary complex. However, the canonical PTB fold cannot be formed without the 
stabilizing hydrophobic residue (pY-5) of the target peptide. Thus, in apo PTB domain 
Ins(1,4,5)P3 could only establish intermediate dynamic contacts with the amine functional groups 
of R67 or Q148 side chains. The second binding site, including the residues L63, Q76 and S107, is 
formed at the interface of the second helix, the loop connecting the first beta strand with the 
second helix and the beginning of the second beta strand. This second PtdIns binding site is 
distinct from the second novel phospho-tyrosine binding site we previously described for Shc 
PTB-bi-β3 complex (41), although it includes several overlapping residues. The third PtdIns 
binding site is restricted to a single but the most perturbed residue of the spectra, F30, which is 
located within the unstructured Shc PTB N-terminus. The chemical shift perturbations in 15N-
HSQC spectrum of apo Shc PTB upon PtdIns(4,5)P2 titration, plotted against the residue number, 
are presented in Figure 13. The inset demonstrates affected residues mapped onto PTB 
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surface, which is colored according to the absolute value of the corresponding chemical shift 
perturbations. 
 
Figure 13. 15N-HSQC spectra showing chemical shifts perturbations in a classical PTB 
binding pocket, the second binding site and F30. Chemical shifts perturbations upon 
PtdIns(4,5)P2 binding to apo Shc PTB domain inset with surface mapping of PTB generated from 
PDB entry 1OY2. The surface is colored acorrding to the corresponding chemical shift 
perturbations, Delta (ppm), from yellow (smallest) to red (largest) and light gray indicating 
missing assignments. Delta (ppm) refers to the combined HN and N chemical shift changes, 
obtained from the equation: Δδ(HN,N) = ((ΔδHN2 + 0.2(ΔδN)2)1/2, where Δδ = δbound – δfree. 
Phospho-Tyrosine(s) versus Phosphatidylinositol Binding in Shc Mediated Integrin Signaling
  
 
32 
 
Story of Integrin Interactions with the Shc - PTB Domain versus Full Length Shc  
Two of the Shc three distinct domains, PTB and SH2, have the potential to bind 
phospho-tyrosines and/or phospholipids. However, in all the experiments performed we did 
not observe any indications of Shc SH2 domain interaction with either PtdIns or β3 integrin 
derived tyrosine(s)-phosphorylated peptides. Thus, we focused our investigation on studying 
the PTB domain alone and comparing it to the full length Shc in order to understand the 
thermodynamic forces driving the interactions. We started with a bi-β3 peptide, which was used 
previously for the structural characterization of the Shc PTB/integrin binary complex (41). We 
found that at 25 °C Kd of this interaction was 5.1 μM (ΔG = -30.17 kJ/mol) and it was 
predominantly driven by enthalpy (ΔH = -22.98 kJ/mol). A representative calorimetric isotherm 
and the corresponding titration curve, depicted in Figure 14a, demonstrate that the interaction 
is exothermic at 25 °C, releasing the heat upon peptide binding with a stoichiometry of about 
1. The driving force of this complex formation is very different from the one defined for the TrkA 
peptide (enthalpy vs. entropy), and it shows a higher specificity, even though the binding affinity 
is about twenty five times weaker (5.14 µM vs. 0.19 µM). We have speculated that the 
secondary binding site for pY747 within the complex might be responsible, at least in parts, for 
the difference. To find out whether this was the case, we ran ITC experiments for the smaller 
c-β3 peptide containing only one terminal pY759 (Figure 14b). Our reasoning appeared to be 
wrong. The shorter (13 vs. 27 residues) mono-phosphorylated peptide had an even higher 
binding affinity with the Kd of 0.34 µM (ΔG = -36.86 kJ/mol) and an even larger favorable 
enthalpy term (ΔH = -25.41 kJ/mol). The thermodynamic analysis of the above interactions is 
presented in Table 5. 
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Figure 14. (a) Bi-β3 peptide and (b) c-β3 peptide binding to Shc PTB domain at 25 °C. 
Shc construct Ligand T (°C) Kd (µM) 
ΔH 
(kJ/mol) 
ΔCp 
(kJ/mol∙K) 
-TΔS 
(kJ/mol) 
ΔG 
(kJ/mol) 
PTB Domain 
bi-β3 
25 5.14 -22.98 
-0.88 
-7.191 -30.17 
12 4.32 -11.52 -17.75 -29.27 
c-β3 
25 0.35 -25.41 
-0.09 
-11.45 -36.86 
12 1.05 -24.18 -8.446 -32.63 
Full Length 
bi-β3 
25 2.84 -28.82 
-0.96 
-2.784 -31.60 
12 5.21 -16.27 -12.55 -28.82 
c-β3 
25 1.33 -7.40 
1.04 
-26.13 -33.53 
12 0.82 -21.03 -12.17 -33.20 
Table 5. Summary of the thermodynamic data for Shc interaction with β3 integrin derived 
mono- and bi-tyrosine-phosphorylated peptides acquired from the ITC measurements 
at two temperature points using full length Shc and PTB domain constructs. 
Next, we decided to find out how the Shc solvent-accessible surface area was affected 
during the reaction. This was accomplished by investigating the change in constant pressure 
heat capacity (ΔCp). ΔCp is given by the slope of the linear regression analysis of ΔH plotted 
Phospho-Tyrosine(s) versus Phosphatidylinositol Binding in Shc Mediated Integrin Signaling
  
 
34 
 
vs. temperature (Equation 17), and it is often independent of temperature within the narrow 
physiological range (reviewed in (61)). Thus, two temperature points, 12 °C and 25 °C, would 
provide an estimate for the slope. For binding reactions, negative ΔCp is expected to 
demonstrate the reduction in protein surface area in contact with the solvent. The larger and 
more negative values reflect a larger surface area buried upon complex formation. Through 
this correlation, structural information of the macromolecular complex could be inferred from 
the thermodynamic parameters. As expected, the longer bi-β3 peptide in complex with Shc 
PTB domain demonstrated a more negative ΔCp of about -0.88 kJ/mol∙K as compared to the 
shorter c-β3 peptide represented by ΔCp of -0.09 kJ/mol∙K (see Table 5 for details). This 
correlates well with the larger solvent-accessible surface area buried upon binding of the longer 
peptide. As we already established that the Shc SH2 domain does not bind to either of the 
above peptides, we decided to confirm that the full length Shc behaves similarly to PTB domain 
alone. To our great surprise that was not the case. We found that while bi-β3 peptide in complex 
with full length Shc showed quite similar ΔCp of about -0.96 kJ/mol∙K, binding of c-β3 peptide 
resulted in a positive ΔCp of about 1.04 kJ/mol∙K. That means that upon complex formation 
with c-β3 peptide more of the Shc solvent-accessible surface area was exposed. The only 
reasonable explanation of this phenomenon that we can imagine is the unraveling of the 
intramolecular interactions between the domains within Shc itself. 
 Δ𝐶𝑝 =
𝜕ΔH
𝜕𝑇
 (17) 
PtdIns Only Weakly Compete with β3-Peptides for Interaction with Shc 
We were also curious about the relation between binding sites for PtdIns and β3-
peptides (bi-β3 and c-β3) on Shc PTB surface. If these sites do not overlap, the presence of β3-
peptide should not interfere with the interaction between PTB and PtdIns; thus, PtdIns should 
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cause concentration-dependent perturbations in the spectra of the PTB-β3-peptides complex. 
In case of a competitive binding between PtdIns and β3-peptides to PTB, since Shc’s affinity 
to bi-β3 and c-β3 is much higher in comparison to its affinity to phospholipids, it is reasonable 
to speculate that integrin tyrosine(s)-phosphorylated CTs can easily replace PtdIns from the 
partially overlapping binding sites on the Shc surface. We have proved the latter scenario by 
using NMR. First, we prepared protein samples of the PTB domain with PtdIns added at 
protein-PtdIns ratios of 1:0, 1:3, 1:5 and 1:15. Then bi-β3 or c-β3 was added to the sample at a 
1:2 protein-to-peptide ratio and 15N-HSQC experiments were performed. The 15N-HSQC 
spectra of both Shc PTB-bi-β3 and Shc PTB-c-β3 complexes in the absence and the presence 
of PtdIns(4)P1, PtdIns(4,5)P2 or Ins(1,4,5)P3 overlap perfectly (an example of the overlapping 
spectra is presented in Figure 15). Therefore, we have confirmed that the binary interfaces 
between Shc PTB and phosphopeptides remained the same in the presence of phospholipids 
added in excess. Also, bound peptides did not allow PtdIns to occupy their partially accessible 
(according to the chemical shifts mapping experiments summarized in Figure 13) potential 
binding sites on the surface of PTB domain. The remaining question was whether PtdIns could 
affect the thermodynamic profiles of Shc interaction with phosphorylated peptides. To test this, 
we investigated the binding of full length Shc and Shc PTB domain with bi-β3 and c-β3 peptides 
in the presence of Ins(1,4,5)P3 by ITC. As expected, our data indicate that the protein samples 
over-saturated by Ins(1,4,5)P3 at 3 to 1 lipid to protein ratio were not much different in Shc binding 
to either of the peptides. The most noticeable difference, observed in a single case, was the 
perturbation in the thermodynamic profile of the full-length Shc titrated by bi-β3, where the 
unfavorable 3 kJ/mol change in enthalpy was almost compensated by the favorable change in 
entropy term, resulting in a slight reduction of Kd value (see Table 6). The impact from Ins(1,4,5)P3 
on the peptide interaction with Shc was also evidenced in this case by the appearance of small 
negative peaks ahead the dominating positive peaks in the titration curve (presented in Figure 
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16), when the reaction was close to saturation. In the absence of the lipid mimetic, the small 
negative peaks were not present. This phenomenon is quite specific, as no similar patterns 
were witnessed in any other ITC experiments performed for studying Shc- bi-β3/c-β3 binding. 
Lastly, to complete the investigation and to confirm the inability of PtdIns to replace the 
phosphopeptides, we performed titrations of PtdIns into Shc PTB complexed with 
phosphorylated peptides (bi-β3 or c-β3, 2:1 peptide to protein ratio). We then monitored 
potential changes in HSQC spectra by NMR or in calorimetric isotherms by ITC. As expected, 
no indications of binding were observed by either method. 
 
Figure 15. 15N-HSQC spectra of Shc PTB pre-satured by Ins(1,4,5)P3 (at protein-PtdIns 
ratios of 1:0, 1:3, 1:5 and 1:15) with bi-β3 added (at a 1:2 protein-to-peptide ratio). The 
lack of difference in the overlaid spectra indicates that integrin tyrosine(s)-phosphorylated β3 
integrin CTs can easily replace PtdIns from the overlapping binding sites on the Shc surface. 
Shc 
construct 
Ligand Kd (µM) ΔH (kJ/mol) 
-TΔS 
(kJ/mol) 
ΔG (kJ/mol) 
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PTB Domain 
bi-β3 4.32 -11.52 -17.75 -29.27 
bi-β3 + Ins(1,4,5)P3 3.65 -12.37 -17.30 -29.66 
c-β3 1.05 -24.18 -8.45 -32.63 
c-β3 + Ins(1,4,5)P3 1.12 -23.62 -8.84 -32.46 
Full Length 
bi-β3 5.21 -16.27 -12.55 -28.82 
bi-β3 + Ins(1,4,5)P3 4.38 -13.87 -15.37 -29.23 
c-β3 0.82 -21.03 -12.17 -33.20 
c-β3 + Ins(1,4,5)P3 0.87 -21.11 -11.96 -33.07 
Table 6. Summary of the thermodynamic data for Shc interaction with β3 integrin derived 
mono- and bi-tyrosine-phosphorylated peptides acquired from the ITC measurements 
at 12°C in the presence and the absence of Ins(1,4,5)P3 
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Figure 16. Full length Shc binding to bi-β3 in the absence (upper) and presence (lower) 
of Ins(1,4,5)P3 at 25 °C 
Discussion 
Scaffold adaptor protein Shc can be recruited through numerous receptors, including 
integrins, growth factors, antigens, cytokines, G-protein-coupled, and hormone receptors (50). 
Interactions of this cytoplasmic protein with specific phospholipids have been proposed as a 
mechanism for its translocation to the membrane (51, 52). Despite vast structural, functional, 
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and biophysical data characterizing Shc involvement in signal transduction from different 
receptors, its interactions with integrins or specific phospholipids are much less studied or 
understood. We have analyzed Shc binding to tyrosine(s) phosphorylated peptides derived 
from β3 integrin and PtdIns using ITC and solution NMR methods. Through these studies we 
have found that PtdIns only weakly compete with phosphorylated integrin cytoplasmic tail for 
Shc PTB binding. This conclusion is based on several observations. First, Shc interactions 
with phosphopeptides are characterized by several orders of magnitude higher affinity than 
binding to PtdIns. Second, Shc interaction with peptides is enthalpy driven in contrast to the 
entropy driven interaction with phospholipids. Third, the overall conformational rearrangement 
of Shc PTB domain upon interaction with the phosphopeptides is coupled with the replacement 
of PtdIns from their binding sites on Shc surface. Lastly, PtdIns cannot replace 
phosphotyrosines from their PTB binding sites and the unoccupied surface is not sufficient to 
stabilize Shc PTB interaction with phospholipids. 
The most interesting finding in this study comes from the thermodynamic analysis of 
mono- and bi-phosphorylated peptides binding to Shc PTB domain vs. the full length Shc. 
Although there are not many differences in the ΔCp of bi-β3 binding, characterized by expected 
negative values of about 0.9 kJ/mol∙K for solvent-accessible surface area buried in both cases, 
there is a striking difference in ΔCp of c-β3 binding. While for PTB domain alone ΔCp is 
expectedly reduced (shorter peptide) but still negative, full length Shc binding is characterized 
by the positive ΔCp value of about 1.0 kJ/mol∙K. This suggests exposure of the originally buried 
solvent-accessible surface area, which is larger than the surface of interaction with mono-
phosphorylated peptide, and this is only possible if the interactions among PTB, CH1 and SH2 
domains within Shc have been disrupted. One of the potential rearrangement schemes for Shc 
domains upon binding different peptides is proposed in Figure 17. In this scenario, Shc is 
recruited to the membrane by the interaction of its PTB domain with PtdIns. While binding of 
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the bi-phosphorylated integrin releases PTB domain from the membrane, β3CT-PTB complex 
may still provide the surface area necessary for intra-molecular interaction with other domains 
of Shc. Contrarily, binding of mono-phosphorylated peptide might result in conformational 
rearrangements leading to a more “extended” Shc structure as PTB domain detaches from the 
lipid bilayer. As Shc is known to be a positive regulator in the MAPK pathway, the recruitment 
of Shc to the activated receptors leads to phosphorylation in the CH1 region at Y239/240 and Y317. 
The phosphorylated tyrosine residues form two consensus binding motifs to the downstream 
adaptor protein Grb2 and the formation of Shc-Grb2 complex eventually leads to the activation 
of the MAPK pathway. We have established previously that integrin cytoplasmic tails are 
capable of accommodating different structural features depending upon their binding partner 
and/or the phosphorylation state (39, 41, 42, 62). Our new data suggests that they can also 
cause variable conformational rearrangements in their targets, as Shc seems to adapt different 
conformations when binds mono/bi-phosphorylated β3 cytoplasmic tail. The plausible biological 
significance of the dexterity in the conformation of Shc may contribute to differential 
phosphorylation in the CH1 region. Although both Y239/240 and Y317 are capable of serving as 
the binding site for Grb2, the biological outcomes emanating from the two phosphorylation 
sites can be significantly different (63). Deciphering this remarkable dexterity should definitely 
aid in better understanding of crucial bidirectional information flow through these distinct 
receptors. 
Phospho-Tyrosine(s) versus Phosphatidylinositol Binding in Shc Mediated Integrin Signaling
  
 
41 
 
 
Figure 17. A model for Shc-mediated integrin signaling at the cytosolic face of the 
plasma membrane. The cytoplasmic tails of integrin αIIb and β3 are shown in red and blue, 
respectively. The PTB domain and SH2 domain of Shc are shown in cyan and gray, 
respectively. The molecules of PtdIns(4,5)P2 and phosphotyrosines are colored acorrding to 
heteroatoms. This descriptive model was generated in Chimera (64) by using PDB entries: 
1OY2, 1TCE, 1S4X, 2KNC, 1SHC, 2LJE, 2L1C, and 
Phosphorylethanolamine/Phosphocholine lipid membrane (65). (a) Shc is recruited to the 
membrane by the interaction of its PTB domain with PtdIns, integrin heterodimer is shown in 
latent state; (b) binding to the activated mono-phosphorylated β3CT via PTB results in the 
conformational rearrangements leading to a more “extended” full length Shc; (c) binding to the 
activated bi-phosphorylated β3CT releases PTB domain from the membrane, though β3CT-
PTB complex may still provide the surface area necessary for the interaction with the other 
internal Shc domains. 
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To conclude, we have: i) confirmed that Shc interacts with both, integrin tyrosine(s)-
phosphorylated cytoplasmic tails and PtdIns lipids, through the same PTB domain (another 
potential hub, SH2 domain, is not involved in these interactions); ii) found that phosphorylated 
peptides binding is enthalpy driven and tighter, while Shc interactions with PtdIns are entropy 
driven and are much weaker; iii) determined that Shc interactions with PtdIns and β3-derived 
peptides are only weakly competitive and are characterized by partially overlapping bindings 
sites; iv) observed thermodynamic indications for potential intramolecular interactions within 
Shc, which could be perturbed by the binding to the phosphorylated receptor; and v) proposed 
a model for Shc-mediated integrin signaling through its recruitment to the lipid bilayer, which 
paves the foundation for the future experiments. 
Research Design and Methods 
Materials and Reagents 
Ins(1,4,5)P3 was purchased from Sigma and Cayman Chemical. (dihexanoyl- or 
dioctonoyl-) PtdIns(4)P1, PtdIns(5)P1 and PtdIns(4,5)P2 were purchased from Cayman Chemical 
(Figure 9). Phosphopeptides derived from β3CT (bi-β3: 
736RAKWDTANNPL(pY)KEATSTFTNIT(pY)RGT762 and c-β3: 750ATSTFTNIT(pY)RGT762) were 
synthesized by NEO-Peptide. 
Cloning and Protein Purification 
The Shc PTB domain (17-207) containing the pET15b vector was transformed into 
Rosetta (DE3) cell line to pursue optimal expression levels (41). SH2 domain (380-473) was 
cloned into NdeI and XhoI sites in pET21b vector and then transformed into a BL21 (DE3) cell 
line. The vector of pET28a-full length Shc (1-473), generously provided by Dr. Ladbury 
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(University of Texas MD Anderson Cancer Center, TX), was expressed in BL21 (DE3) cell line 
as well. Typically, 10 ml overnight culture was used to inoculate 1 liter LB broth. Cells were 
grown at 37 °C until OD600 reached 0.6. At this point the culture was cooled to room 
temperature and then the overnight overexpression was induced by 1 mM isopropyl-β-D-
thiogalactopyranoside. Harvested cells were kept at -20 °C for future purification or 
resuspended in lysis buffer supplemented with protease inhibitors. Cells were further lysed by 
french press and the cell debris was removed by centrifugation at 18,000 rpm at 4 °C. The N-
terminal His-tag fused PTB domain and full length Shc, and the C-terminal His-tag fused SH2 
domain were first purified under native conditions with Ni-NTA resin (QIAGEN) using the 
standard protocol followed by a buffer exchange to 50 mM Tris, pH 7.5, 100 mM NaCl, 5 mM 
β-mercaptoethanol in a Superdex-75 column (GE Healthcare) where all three recombinant 
proteins showed a proper folding in monomeric state (Figure 18). The overexpression of the 
target protein and the purified protein were confirmed by SDS-PAGE and the bands of the 
expected mass were observed. The determination of protein concentration by UV 
measurement was consistent with Bradford assay. 
Phospho-Tyrosine(s) versus Phosphatidylinositol Binding in Shc Mediated Integrin Signaling
  
 
44 
 
 
Figure 18. Chromatograms from Size-exclusion chromatography in a Superdex-75 
column and SDS-PAGE gel pictures of full-length Shc, Shc PTB domain and SH2 domain. 
All three recombinant proteins are shown in monomeric state with a good purity after the 
purification process. 
ITC Experiments 
Calorimetric measurements of a full length Shc, PTB domain, and SH2 domain to β3 
phosphopeptides or PtdIns were performed on a low volume Nano ITC (TA Instruments). All 
experiments were carried out in a buffer of 50 mM Tris, pH 7.5, 100 mM NaCl, 5 mM β-
mercaptoethanol (unless described otherwise) at 12 or 25 °C with a stirring speed of 250 rpm 
to minimize the precipitation of the protein. 300 second time intervals were set between 
injections. The concentration of protein samples was determined by UV measurements. The 
titrants (β3 phosphopeptides or PtdIns) were prepared in the same buffer by the dilution of 
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higher concentration stocks. The concentrations of the protein ranged from 30 μM to 150 μM. 
The concentration of protein was examined after each ITC experiment by UV to ensure the 
stability of proteins under the test condition. The analysis of the data was done with 
NanoAnalyze Software (TA Instruments) suite using an “independent” model. In all cases, a 
stoichiometry of 1 ± 0.15 was revealed for the interaction between protein and β3 
phosphopeptides/PtdIns. 
15N-HSQC Titration by NMR 
15N-labelled recombinant proteins were overexpressed in M9 medium supplemented 
with 15NH4Cl as the sole nitrogen source. The same purification procedures as described above 
were followed. NMR samples of 100-200 µM were prepared in a buffer of 50 mM Tris, pH 7.5, 
100 mM NaCl, 5 mM β-mercaptoethanol, 7% D2O, 1 mM 4,4-dimethyl-4-silapentane-1-sulfonic 
acid as the internal standard. 15N-HSQC titration experiments were performed on a 
Varian/Agilent Inova 600 MHz spectrometer equipped with inverse-triple resonance cryo-probe 
at 35 °C. All spectra were processed with NMRPipe (66) and analyzed in CCPNmr Analysis 
software suite (67). 
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Chapter 5 Vγ9Vδ2 T cells in the Immune System 
Overview of the Immune System in Humans 
The immune system detects and fights against pathogens including foreign proteins, 
virus, bacteria and even cancer cells. The immune system in many species including humans 
can be classified into two sub-systems (Figure 19), non-specific or innate immune system, and 
specific or adaptive immune system. The innate immune system recognizes the conserved 
features of pathogens which successfully enters the organisms and is quickly activated to 
attack the invaders; however, it defends pathogens in a generic way and cannot develop 
immunological memory. Another function the innate immune system has is to work as APCs 
to activate the adaptive immune system. The adaptive immune system, on the other hand, is 
able creates immunological memory after the initial exposure to the pathogens and develops 
long-lasting immunity.  
 
Figure 19. The innate and adaptive immune response. Figure taken from Alberts B, 
Johnson A, Lewis J, et al. Molecular Biology of the Cell. 4th edition. New York: Garland Science; 
2002. Figure 24-1, Innate and adaptive immune responses. 
The adaptive immune system produces both humoral (antibody-mediated) response 
and cell-mediated response (Figure 20). In humoral immunity, extracellular antigens are 
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targeted and antibodies are secreted to destroy the antigens. Cell-mediated immunity is 
triggered when intracellular infections occur and does not involve antibodies. 
 
Figure 20. Cell-mediated immune response and antibody response. Figure taken from 
Alberts B, Johnson A, Lewis J, et al. Molecular Biology of the Cell. 4th edition. New York: 
Garland Science; 2002. Lymphocytes and the Cellular Basis of Adaptive Immunity. 
Lymphocytes: B Cells and T Cells 
Lymphocytes are a type of white blood cells in immune system and responsible for 
adaptive immune responses to infections and other foreign substances, and host defense 
against diseases. There are two primary types of lymphocytes, B cells and T cells. B cells are 
largely involved in the humoral immune response (Figure 21). The activation of B cells is 
triggered by antigens usually in a T cell-dependent manner. B cells then proliferate and 
differentiate in to plasma cells producing an antibody targeting the specific antigen the B cell 
is exposed to. In addition, B cells can internalize and process antigens and then present the 
peptides to T cells using MHC II molecules. Thus B cells belong to the family of professional 
APCs. 
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Figure 21. Humoral immune response by B cells activated in presence of helper CD4+ T 
cells. Figure taken from Janeway CA Jr, Travers P, Walport M, et al. Immunobiology: The 
Immune System in Health and Disease. 5th edition. New York: Garland Science; 2001. 
Chapter 9, The Humoral Immune Response. 
T cells play a central role in the cell-mediated immune response. In the lineage of T 
cells, T cells expressing a αβ TCR, αβ T cells, constitute the majority of T cells in humans. αβ 
T cells are among the best studied T cell lineage and often considered as “conventional”. αβ 
T cells can be further categorized as either “helper CD4+ T cells”, which recognize antigens 
via MHC II (Figure 22) and help to activate the other immune cells (such B cells, Figure 23) by 
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releasing cytokines, or “cytoxic CD8+ T cells”, which recognize antigens via MHC I and directly 
kill target cells including cancerous, infected and damaged cells (Figure 22). The recognition 
between αβ TCR and antigen peptides has low binding affinity and specificity. 
 
Figure 22. Helper CD4+ T cells vs. cytoxic CD8+ T cells in antigen recognition. Figure 
take from reference (68). 
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Figure 23. Comparison of the signals required to activate a helper T cell and a B cell. 
Figure taken from Alberts B, Johnson A, Lewis J, et al. Molecular Biology of the Cell. 4th edition. 
New York: Garland Science; 2002. Helper T Cells and Lymphocyte Activation. 
On the other hand, T cells expressing a γδ TCR, γδ T cells, comprising only a small 
percentage of the circulating T cells, are far less understood. The antigenic specificities and 
functional features of γδ T cells are being investigated actively and extensively (69-73). γδ T 
cells show innate cell-like features allowing its early activation induced by conserved stress-
induced ligands. In addition, γδ T cells are capable of producing cytokines rapidly in case of 
tissue stress (74). Most of the molecular mechanism of the activation of γδ T cells remains 
enigmatic. Nonetheless, γδ T cells garner increasing interest due to its killer cell-like cytotoxic 
activity against cancer cells (74). 
Vγ9Vδ2 T Cells 
In humans and non-human primates, Vγ9Vδ2 T cells represents the majority of γδ T 
cells circulating in blood and account for between 1% and 10% of total blood T cells (69). 
Vγ9Vδ2 T cells express a TCR containing a Vδ2 chain paired with a Vγ9 chain. Both Vδ2 and 
Vγ9 genes are evolutionarily conserved in primates (75) and such a pairing only exists in 
humans and primates (76). The Vγ9Vδ2 T cells can rapidly acquire characteristics of 
professional APCs after activation (77). Vγ9Vδ2 T cells exhibit anti-microbial and anti-tumor 
properties (73), which make them a promising target for immunotherapies for a variety of 
diseases. 
Structurally, Vγ9Vδ2 TCR has a smaller angle between Vγ and Cγ domains compared 
to αβ TCR (110° vs. 147°, Figure 24). The V domains of Vγ9Vδ2 TCR are generally similar to 
αβ TCR; however the C domains are remarkably different, which may provide the molecular 
basis of a distinct recognition/signaling mechanism compared to αβ TCR. 
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Figure 24. αβ TCR vs. Vγ9Vδ2 TCR. Figure modified from reference (78). 
Activation of Vγ9Vδ2 T Cells by Phosphoantigens  
Distinct from αβ T cells, γδ T cells can be activated in a MHC-independent manner. In 
humans, the activation of Vγ9Vδ2 T cells can be triggered by non-peptide phosphorous-
containing small molecules also known as phosphoantigens. The Vγ9Vδ2 T cells are sensitive 
to the di-phosphorylated isoprenoid intermediates (E)-4-hydroxy-3-methyl-but-2-enyl 
pyrophosphate (HMBPP), which is produced by bacterial in the non-mevalonate pathway 
(Figure 25), leading to Vγ9Vδ2 T cell anti-microbial functions. Cancer cells can produce 
another natural phosphoantigen, isopentenyl pyrophosphate (IPP), from the human 
mevalonate pathway (Figure 25). IPP can also activate Vγ9Vδ2 T cells resulting in rapid 
expansion and cytotoxicity against cancer cells. 
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Figure 25. Isoprenoid biosynthesis in bacterial and human. Figure taken from reference 
(79). 
Novel γδ T cells-based immunotherapeutical approaches have been proved promising 
in the treatment for a variety of diseases including cancers (73, 80). Here we summarized 
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briefly the rationale of Vγ9Vδ2 T cells cells-based cancer immunotherapies (73, 80-83). First, 
Vγ9Vδ2 T cells are capable of infiltrating tumors and accumulating at tumor sites. Secondly, 
Vγ9Vδ2 T cells exhibit a potent cytotoxicity against a broad range of malignancies while 
sparing normal cells by secreting cytokines. Thirdly, the activation of γδ T cells can be triggered 
by exogenous supply of phosphoantigens or bioaccumulation of endogenous 
phosphoantigens (80). 
A number of selective agonists of Vγ9Vδ2 T cells have been developed and are being 
tested under clinical trials for a variety of malignancies. As reviewed in reference (79), 
phosphoantigens to activate Vγ9Vδ2 T cells can be classified into two direct and indirect 
categories. Direct phosphoantigens, such as HMBPP and IPP and synthetic analogs from 
them, are able to directly bind to BTN3A1, a critical positive regulator in Vγ9Vδ2 T cell 
activation. In contrast, the mentality of using indirect phosphoantigens to activate Vγ9Vδ2 T 
cells is largely based on inhibition the human isoprenoid metabolism, particularly farnesyl 
diphosphate synthase, to elevate the level of the direct phosphoantigen of IPP (Figure 25). 
Some FDA-approved bisphosphonates for the treatment of other diseases were found 
to have anti-tumor activities (84), which were believed to be associated with their antagonistic 
effect of Vγ9Vδ2 T cells. Zoledronate (Figure 26), a third-generation bisphosphonate drugs 
used for osteolysis and high blood calcium levels, is an effective farnesyl diphosphate synthase 
inhibitor (79). BrHPP, a synthetic analog of HMBPP, was found to trigger Vγ9Vδ2 T cell 
activation at nanomolar concentrations with minimal unspecific binding at micromolar 
concentrations (85). Zoledronate and BrHPP, representing indirect and direct 
phosphoantigens, respectively, have been evaluated in a handful clinical studies for a variety 
of cancers (79, 80). Although treatment Zoledronate or BrHPP with IL-2 have been shown to 
have good safety and some efficacy for certain malignancies, mixed results indicate 
phosphoantigens may have different stimulation patterns. Thus a better understanding of the 
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underlying molecular mechanism how phosphoantigens cause activation of Vγ9Vδ2 T cells is 
undoubtedly crucial for future studies on phosphoantigens in Vγ9Vδ2 T cell-based 
immunotherapies. 
 
Figure 26. Structure of zoledronate 
 
Figure 27. Structure of BrHPP 
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BTN3A1 in Activation of Vγ9Vδ2 T Cells 
BTN3A1, the butyrophilin subfamily 3 member A1, is a B7 immunoglobulin superfamily 
protein. By far, 13 members of the butyrophilin family have been identified (86). Enriched 
content of butyrophilins was detected in milk lipid globules. Thus butyrophilins were originally 
believed to be important only in lactation and milk production (87). Due to their structural 
features of B7 superfmily of co-stimulatory molecules (Figure 28), and their expression in 
immune cells and cells closely interacting with immune cells, butyrophilines have been studied 
actively to explore their immunological functions as nicely reviewed in a recent reference (86).  
B7 family members feature a protein architecture of extrcellular IgV and IgC domains, 
a transmembrane region and a short cytoplasmic tail (Figure 28). Butyrophilin and butyrophilin-
like family members retain the same IgV-IgC extracellular structure but, distinct from other B7 
family members, comprise a B30.2 (PRY/SPRY) intracellular domain following the 
transmembrane region (Figure 28). 
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Figure 28. Protein architecture of B7 family and butyrophilin superfamilies. Figure taken 
from (86). 
Recently, BTN3A1 has been identified as the binding partners for direct 
phosphoantigens (such as HMBPP and IPP), establishing its significance in Vγ9Vδ2 T cell 
activation. The fact that the direct interaction between BTN3A1 and phosphoantigens leads to 
the following Vγ9Vδ2 T cell activation has been recognized. Models of intracellular and 
extracellular binding of BTN3A1 to phosphoantigens have been proposed by different groups. 
We used a phosphoantigen prodrug approach to demonstrate this strategy has superior 
potency in Vγ9Vδ2 T cell activation compared to other current phosphoantigens clinically used. 
Furthermore, our biophysical data from NMR and ITC undoubtedly suggests an intracellular 
binding of BTN3A1 to phosphoantigens. With those findings, the underlying molecular 
mechanisms of phosphoantigen-induced Vγ9Vδ2 T cell activation has been advanced and a 
prodrug approach provides new possibilities for development of phosphoantigens for Vγ9Vδ2 
T cell-based immunotherapies. 
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Chapter 6 Do Phosphoantigens Bind to the Extracellular IgV Domain of 
BTN3A1? 
Critical review on reference (88) 
The Extracellular Binding Model of IgV-Phosphoantigen 
During the course of these studies, two groups reported binding of phosphoantigens to 
BTN3A1 via conflicting mechanisms, extracellular vs. intracellular. Initially, De Libero and 
colleagues demonstrated extracellular binding (88), whereas a recent paper by Adams clearly 
showed intracellular binding (89). The exact binding site on BTN3A1 for phosphoantigens is a 
matter of debate. However, our biological and biophysical studies clearly suggest an 
intracellular interaction between BTN3A1 and phosphoantigens as also confirmed by other 
independent studies (Chapter 7). 
De Libero and colleagues purposed a model where the extracellular IgV domain of 
BTN3A1 binds phosphoantigens suggesting BTN3A1 functions as the antigen-presenting 
molecule for the activation of Vγ9Vδ2 T cells. In this study, biophysical evidence showing direct 
extracellular binding of BTN3A1 IgV domain to phosphoantigens are mainly from three 
methods: X-ray Crystallization, Mass spectroscopy and SPR analysis. Here is the argument 
that the results presented in the paper may be deceptive leading to the extracellular model. 
Crystal Structures of IgV Complexed with Phosphoantigens 
Two main structures, IgV-IPP (PDB entry: 4JKW) and IgV-HMBPP (PDB entry: 4K55), 
were determined by X-ray with a resolution of 2.0 Å. The protein did resemble an 
immunoglobulin V domain structure. However, after a closer investigation on the molecular 
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details of the binding site, the electron density map shows an almost identical “donut” shape 
for both ligands, IPP and HMBPP. Both IPP and HMBPP have a structure distinct from a 
circular shape (Figure 32). Indeed, both ligands can only occupy half of the “donut” leaving a 
vacancy for the other half (Figure 29). This strongly suggests a poor fitting of the 
phosphoantigen onto the electron density map and leads to the question of what the ligand is 
exactly in the structures. Our hypothesis was that PEG molecules, the co-precipitant regent 
used for the crystallization, bind to the Lys39 residue of IgV domain. Another structure from 
PDB clearly shows a PEG molecule can adopt a circular shape during crystallization and wrap 
itself around the side-chain of a Lys residue (Figure 30) (90, 91). Our speculations were 
confirmed by another independent research group (Figure 31) (89). 
 
Figure 29. Electron density of BTN3A1 IgV-phosphoantigen structures constructed from 
PDB entries: 4JKW and 4K55 showing a poor fitting for both IPP and HMBPP 
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Figure 30. PEG molecules in a circular shape with a Lysine residue in the center (PDB 
entry: 3FFR). Figure taken from Crystal structure of phosphoserine aminotransferase SerC 
(EC 2.6.1.52) (YP_677612.1) from CYTOPHAGA HUTCHINSONII ATCC 33406 at 1.75 A 
resolution (To be published). 
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Figure 31. PEG molecules showing a better fitting than HMBPP (PDB entry: 4K55) and 
IPP (PDB entry: 4JKW). Figure taken from reference (89).  
Mass Spectroscopy and SPR Analysis of the IgV-Phosphoantigen Interaction 
In the investigation of the direct IgV-phosphoantigen interaction claimed by De Libero 
and colleagues (88), IPP and GDP (as a negative control) were chosen to perform the Mass 
Spectroscopy study. Considering stronger affinity of HMBPP, it is surprising to see HMBPP 
was not tested for reasons not explicitly reported. The interaction between IgV and IPP with 
1:1 stoichiometry was confirmed in an iso-trap mass spectrometer with electrospray ionization 
as the de-convoluted spectrum of IgV-IPP showed an increase of 244 Da which is close to the 
molecular mass of IPP, 246 Da. Considering that the Kd is in low-micromolar range, it is 
debatable if the non-covalently bound IPP can survive the ionization during the experiment. 
Mass Spectroscopy may not be the perfect tool for this type of interactions as extreme cautions 
need to be taken in the search for the optimal conditions (92). In addition, few Mass 
Spectroscopy data other than the de-convoluted spectra was provided to support the result. 
The kinetics of IgV-IPP and IgV-HMBPP interactions were assessed using SPR by De 
Libero and colleagues (88). A stronger binding was suggested for HMBPP than IPP, with 
association rate constants of 76.6 M-1s-1, 746.9 M-1s-1 and dissociation rate constants of 5.35 
× 10-3 s-1, 2.28 × 10-3 s-1 for IPP and HMBPP, respectively. The equilibrium binding constants 
(Kd) were calculated to be 69.6 µM for IPP and 3.06 µM for HMBPP. However, one of 
disadvantages of SPR is that it cannot effectively distinguish specific from non-specific 
bindings. Additionally, the SPR studies of ligand bindings of low molecular weight usually do 
not have a good sensitivity (93-95). Thus we argue that the confirmation of a specific and direct 
interaction between the extracellular IgV domain and phosphoantigens by SPR lacks credibility. 
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In summary, the extracellular binding presented by De Libero and colleagues is unclear 
as all of three main biophysical experiments had noticeable flaws. Almost at the same time, 
Adams group and our group published two independent studies. Both studies undoubtedly 
suggest an intracellular binding of BTN3A1 to phosphoantigens. Confirmed by other following 
independent studies (96), the intracellular binding model of BTN3A1 to phosphoantigens has 
been widely acknowledged. A better understanding of the interaction between BTN3A1 and 
phosphoantigens sets the right course for future studies on phosphoantigens in Vγ9Vδ2 T cell 
activation, and lays the groundwork for development of next-generation Vγ9Vδ2 T cell-based 
immunotherapies. 
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Chapter 7 Intracellular Binding of BTN3A1 to Phosphoantigens 
Based on Hsiao, C.H.C., Lin, X., Barney, R.J., Shippy, R.R., Li, J., Vinogradova, O., Wiemer, 
D.F. and Wiemer, A.J., 2014. Synthesis of a phosphoantigen prodrug that potently activates 
Vγ9Vδ2 T-lymphocytes. Chemistry & biology, 21(8), pp.945-954. 
 
A POM-protected Phosphoantigen is Highly Potent in Vγ9Vδ2 Stimulation. 
Drugs of phosphates and phosphonates are being explored exceedingly in anticancer 
and antiviral therapy. Prodrugs of phosphates and phosphonates have significantly improved 
bioavailability, membrane permeability and plasma stability (97). Small and highly charged 
molecules (such as phosphoantigens) exhibit low cellular concentration due to the need for 
endocytic uptake. Prodrugs (such as POM-protected molecules) mask the negative charged 
groups ensuring a passive diffusion across the cell membrane. After the cellular entry, the 
POM-protecting groups are removed by cellular esterases generating the functional 
phosphoantigens. 
Compound 1a, a modest phosphoantigen (98), was chosen for our prodrug strategy 
due to its better chemical stability against phosphatase metabolism. A series of protected 
compounds (Figure 32) were synthesized and tested in human peripheral blood Vγ9Vδ2 T cell 
stimulation and the cell-based assay provided very exciting results (Table 7). 
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Figure 32. Chemical structures of phosphoantigens used in the study 
Compound EC50 (μM) 
Fold 
difference 
from HMBPP 
Fold 
difference 
from 1a 
IC50 
(μM) 
Selectivity 
index 
HMBPP 0.00051 1.0 NA 0.50 980 
IPP 36 71000 NA ND ND 
Risedronate 1.6 3100 NA 61 38 
1a 4.0 7800 1 ND ND 
1b 0.0054 10 740 0.60 110 
1c 0.50 980 8 8.6 17 
1d > 10 > 19000 NA ND ND 
NA, not applicable; ND, not determined. 
Table 7. Activity of compounds for expansion of Vγ9Vδ2 T Cells from human peripheral 
blood mononuclear cells and inhibition of cell viability 
Compound 1a showed a moderate potency in Vγ9Vδ2 T cell stimulation (Table 7). The 
dimethyl phosphonate, compound 1d, was predicted to be inactive for its metabolism stability 
(99) and indeed was not able to stimulate Vγ9Vδ2 T cell (Table 7). Compound 1c is compound 
1d with a labile POM group replacing one of the two methyl groups (Figure 32). The 
introduction of a POM group was able to restore the stimulatory effect and was more potent 
than compound 1a (Table 7). The double POM-protected or bis-POM phosphoantigen, 
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compound 1d, exhibited the highest potency among compounds 1a-1d and provided an EC50 
of 0.0054 µM (Table 7). The results proved the concept of using a bis-POM phosphoantigen 
to achieve Vγ9Vδ2 T cell stimulation.  
HMBPP, a potent direct phosphoantigen, showed an EC50 of 0.00051 µM which is the 
strongest in all the phosphoantigens tested. However, due to the highly-charged negative 
groups, HMBPP suffers from poor pharmacokinetic properties, rapid plasma clearance and 
low membrane permeability (100). Compared to HMBPP, our bis-POM phosphoantigens, 
compound 1b, showed a much higher potency in our 2-hr Vγ9Vδ2 T cell stimulation (Figure 
33D). The fast stimulatory effect is believed to be a result from the enhanced uptake of 
compound 1b. Although less potent than HMBPP, compound 1b was still able to stimulate 
Vγ9Vδ2 T cell at low nanomolar concentrations.  
 
Figure 33. Bis-POM prodrug compound 1b functions as a direct phosphoantigen with 
elevated potency relative to compound 1a and HMBPP. * indicates statistical significance. 
Risedronate and other indirect phosphoantigens are known to activate Vγ9Vδ2 T cell 
by inhibiting farnesyl diphosphate synthase in the human isoprenoid metabolism (Figure 25). 
The resulted cellular accumulation of IPP, the natural direct antigen, induces stimulation of 
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Vγ9Vδ2 T cells. To prove that our bis-POM compound 1b works as a direct phosphoantigen, 
compound 1b was compared with Risedronate in Vγ9Vδ2 T cell stimulation with treatment of 
lovastatin (Figure 33C). Lovastatin inhibits 3-hydroxy-3-methylglutaryl-coenzyme A reductase 
upstream of farnesyl diphosphate synthase, and counters the induced accumulation of IPP by 
indirect phosphoantigens such as Risedronate. The stimulated Vγ9Vδ2 T cell proliferation by 
compound 1b was not decreased by treatment of lovastatin, which notably abated the 
stimulatory effect of Risedronate. This study, and the biophysical evidence for a direct 
intracellular between BTN3A1 and compound 1a, prove our hypothesis that our bis-POM 
compound 1b is a direct-acting phosphoantigen. 
The BTN3A1 PRY/SPRY (B30.2) Domain Directly Binds Phosphoantigens. 
It recently was reported that BTN3A1 is required for phosphoantigen detection by 
Vγ9Vδ2 T cells (88, 101, 102). However, the exact region of BTN3A1 where phosphoantigens 
bind is a matter of debate (88, 101). Based on the 740x increase in activity of the bis-POM 
prodrug, we hypothesized that intracellular binding occurs, which is in contrast to the model of 
extracellular binding to the immunoglobulin-like V (IgV) (88). To determine whether the 
BTN3A1-antigen complex forms intracellularly or extracellularly, we expressed the 
recombinant extracellular IgV domain, the intracellular PRY/SPRY (B30.2) domain, and the full 
intracellular domain (BFI) and purified the soluble proteins. First, we verified the conformations 
of the constructs by NMR, and, according to the nicely dispersed 1H-15NHeteronuclear Single 
Quantum Correlation (HSQC) spectra, all the recombinant proteins are well folded and remain 
in monomeric state. Most of the amide resonance frequencies for PRY/SPRY domain 
overlapped with the peaks in the spectra for BFI (presented overlaid in Figure 34). This 
suggests the structure of PRY/SPRY domain in isolated form and in the context of the full-
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length protein remains the same and that the 68-residue membrane proximal region does not 
interact with the PRY/SPRY domain intramolecularly.  
 
Figure 34. Evidence for the absence of major 18 intramolecular interactions between the 
68-residue membrane-proximal region and PRY/SPRY domain: HSQC spectra of BFI 
(black) and PRY/SPRY (gray) 
We performed ITC to measure the interactions between these three BTN3A1 
constructs and HMBPP (Figure 35A). While no binding was observed with the extracellular 
BTN3A1 IgV domain, both the intracellular PRY/SPRY (B30.2) domain and the BFI domain 
showed strong binding with dissociation constants (Kd) of 1.61 μM and 1.54 μM, respectively. 
The interaction of HMBPP with BTN3A1 was enthalpy-driven with an unfavorable entropy 
change. HMBPP binding to the full intracellular domain (ΔH = -51.9 kJ/mol and TΔS = -18.7 
kJ/mol) and the PRY/SPRY domain (ΔH = -49.4 kJ/mol and TΔS = -16.4 kJ/mol) shares very 
similar enthalpy and entropy terms, which reveals the binding site on BTN3A1 for 
phosphoantigens is enclosed in the PRY/SPRY domain (Table 8). 1H-15N HSQC titrations of 
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HMBPP agreed with the ITC results. While there were no chemical shift perturbations in the 
spectrum for the IgV domain upon HMBPP titration (Figure 36) the effects from HMBPP on the 
spectra of BFI and PRY/SPRY were very pronounced. HMBPP-concentration-dependent 
chemical shift perturbations were observed in the spectra for both BFI (Figure 37A) and the 
PRY/SPRY domain (Figure 37B) and reached saturation at an HMBPP:protein ratio of 3:1. 
Combining ITC and NMR data, we have demonstrated that HMBPP interacts with BTN3A1 at 
its intracellular domain at 1:1 ratio and is likely capable of inducing significant conformational 
rearrangements in the intracellular domain of BTN3A1. 
 
Figure 35. Binding of HMBPP and Compound 1a to the Intracellular Domain of BTN3A1. 
(A) Isothermal titration calorimetry plots for the interaction of HMBPP with the extracellular IgV 
domain (gray line/dots), the full intracellular domain (BFI) (black line/dots), or the isolated 
PRY/SPRY (B30.2) domain (red line/dots). (B) Isothermal titration calorimetry plots for the 
interaction of the full intracellular domain (BFI) of BTN3A1 with HMBPP in the absence of 
compound 1a (red line/dots), or the presence of 10x compound 1a (gray line/dots), or 100x 
compound 1a (blue line/dots). 
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Protein or protein-ligand complex Ligand 
Kd 
µM 
ΔH 
kJ/mol 
TΔS 
kJ/mol 
ΔG 
kJ/mol 
IgV 
HMBPP 
No binding 
PRY/SPRY 1.61 -49.4 -16.4 -33.0 
BFI 1.54 -51.9 -18.7 -33.2 
BFI + Compound 1a 
1:10 
HMBPP 
1.70 -49.1 -16.2 -32.9 
1:100 1.26 -28.3 5.33 -33.6 
BFI + IPP 
1:10 
HMBPP 
1.15 -46.6 -12.7 -33.9 
1:100 2.55 -38.7 -6.78 -31.9 
BFI C-HDMAPP 1.95 -47.1 -14.5 -32.6 
Table 8. Summary of the thermodynamic data derived from the ITC measurements using 
different ligands 
 
Figure 36. Evidence for the absence of interaction between HMBPP and the extracellular 
IgV domain of BTN3A1. HSQC of spectra of free IgV domain (black), IgV + HMBPP at 1:1 
protein-to-compound ratio (blue) and IgV + HMBPP at 1:3 protein-to-compound ratio (red). The 
three spectra overlap perfectly indicating no interaction between HMBPP and the IgV domain. 
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Figure 37. 1H-15N  HSQC titration of HMBPP into the full-length intracellular domain and 
the PRY/SPRY domain of BTN3A1. Compared to the PRY/SPRY domain, the full-length 
intracellular domain of BTN3A1 (BFI) includes an additional membrane-proximal region of 68 
residues at the N-terminus, which is demonstrated to be involved in the interaction with HMBPP 
and to undergo significant structural changes upon binding. (A) Chemical shift perturbations 
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for the interaction of HMBPP and BFI at ratios of 0:1 (black), 1:1 (blue), 3:1 (red). (B) Chemical 
shift perturbations for the interaction of HMBPP and the PRY/SPRY domain at ratios of 0:1 
(gray), 1:1 (orange), 3:1 (green). (C) Evidence for the involvement of the 68-residues 
membrane-proximal region in interaction with HMBPP: HSQC spectra of the free BFI (black), 
BFI + HMBPP at 1:3 ratio (red) and PRY/SPRY + HMBPP at 1:3 ratio (green). Peaks which 
belong to the 68-residue membrane-proximal region are absent in the spectrum of PRY/SPRY 
domain. Arrows indicate the peaks corresponding to the amides from this region that have 
showed remarkable shifts upon binding to HMBPP, thus suggesting significant structural 
rearrangements. 
To determine whether binding was specific to HMBPP or a general property of 
phosphoantigens, we also tested whether another potent phosphoantigen, C-HDMAPP, could 
bind to internal domain (Figure 38). C-HDMAPP is a phosphonate analog of HBMPP (98). 
Interestingly, C-HDMAPP exhibited similar energetics relative to HMBPP when binding to the 
PRY/SPRY domain (Kd = 1.95 μM, ΔH = -47.1 kJ/mol, TΔS = -14.5 kJ/mol). The data reveals 
that both HMBPP and C-HDMAPP bind with high affinity to the intracellular PRY/SPRY (B30.2) 
domain but not the extracellular V domain. C-HDMAPP has a slightly weaker interaction which 
is consistent with its activity in cellular assays (98). Therefore, we have demonstrated that two 
different phosphoantigens bind strongly to the intracellular domain of BTN3A1.  
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Figure 38. Binding of C-HDMAPP to the BTN3A1 full intracellular domain 
Because IPP also acts as a direct phosphoantigen in cellular assays, we tested its 
ability to interact with BTN3A1. However, we were unable to measure directly the binding of 
IPP to BTN3A1 by ITC.  This is perhaps not surprising, given that the activity in cellular assays 
is approximately 71,000 fold less for IPP relative to HMBPP (Table 8) making the projected 
dissociation constant well outside of the detection limit of ITC. Therefore, we performed a 
competition ITC study to determine whether increasing concentrations of IPP would affect the 
binding of HMBPP to BTN3A1 (Figure 39). IPP dose-dependently decreased the favorable 
enthalpy of HMBPP binding from a ΔH of -51.9 kJ/mol to -47.7 kJ/mol and -38.7 kJ/mol at 
IPP:BTN3A1 ratios of 10:1 and 100:1, respectively (Table 8). IPP also dose-dependently made 
more favorable the TΔS term of HMBPP binding, changing it from -18.7 kJ/mol to -12.7 kJ/mol 
and -6.78 kJ/mol at IPP:BTN3A1 ratios of 10:1 and 100:1 respectively. Taken together, the 
data show that IPP binds to BTN3A1 with a much weaker affinity compared to HMBPP and 
that both compounds compete for the same binding site within the PRY/SPRY domain. 
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Figure 39. Binding of HMBPP to the BTN3A1 full intracellular domain in the presence of 
IPP (no IPP, red line; IPP:BTN3A1=10:1, gray line; IPP:BTN3A1=100:1, blue line) 
Because compound 1b is expected to undergo metabolic cleavage, resulting in 
accumulation of compound 1a, we examined the binding affinity between compound 1a and 
the BTN3A1 PRY/SPRY domain. Like IPP, the binding affinity of 1a was undetectable in ITC 
when using compound 1a as the sole ligand, as we had purposely chosen a weak 
phosphoantigen for the prodrug studies. However, as expected, compound 1a had a markedly 
stronger effect on the HMBPP binding to the PRY/SPRY domain relative to IPP (Figure 35). 
Like IPP, compound 1a dose-dependently decreased the favorable enthalpy of HMBPP 
binding to BTN3A1 (Table 8). These effects also were measured at 1a:BTN3A1 ratios of 
0:1(ΔH of -51.9 kJ/mol), 10:1 (-49.1 kJ/mol) and 100:1 (-28.5 kJ/mol). Compound 1a also dose-
dependently made more favorable the TΔS term of HMBPP binding at IPP:BTN3A1 ratios of 
10:1 (-16.2 kJ/mol) and 100:1 (+5.19 kJ/mol). These data fit well with the cellular data in that 
1a is a more potent phosphoantigen relative to IPP and would be expected to have a stronger 
effect. Perhaps surprisingly, the entropy term became positive at the highest concentration of 
1a. This finding demonstrates that the prenyl alcohol and/or the olefin position play a more 
important role in the phosphoantigen-BTN3A1 interaction as compared to the distal phosphate 
group. Thus, according to ITC data, compound 1a may induce conformational changes in the 
intracellular domain of BTN3A1 similar to the ones induced by the stronger interaction with 
HMBPP and absent in the interface with IPP.  
To confirm that IPP and compound 1a do have direct interactions with the intracellular 
domain of BTN3A1, 1H-15N  HSQC titrations of IPP and compound 1a into BFI were performed 
at ligand:protein molar ratios of 0:1, 10:1 and 100:1. Both IPP (Figure 40A) and compound 1a 
(Figure 40B) showed concentration-dependent perturbations in the spectra. These two sets of 
titration data demonstrate that both IPP and compound 1a bind to BFI at a similar binding site 
with only a limited number of distinct differences in amide chemical shift perturbations between 
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the two. In addition, the spectrum of compound 1a, but not IPP, shows several chemical shift 
perturbations identical to the ones observed in the titration of HMBPP (marked by arrows on 
Figure 40C). Thus our NMR and ITC results are mutually consistent and suggest that binding 
sites for IPP and compound 1a on the PRY/SPRY domain are quite similar, although each 
compound is also involved in unique interactions with BTN3A1. 
Intracellular Binding of BTN3A1 to Phosphoantigens  
 
74 
 
 
Intracellular Binding of BTN3A1 to Phosphoantigens  
 
75 
 
Figure 40. 1H-15N  HSQC titration of IPP and compound 1a into the full-length intracellular 
domain of BTN3A1 (BFI). (A) Chemical shift perturbations for the interaction of IPP and BFI 
at ratios of 0:1 (black), 10:1 (blue), 100:1 (red). (B) Chemical shift perturbations for the 
interaction of compound 1a and BFI at ratios of 0:1 (gray), 10:1 (orange), 100:1 (green). (C) 
Comparison of BFI chemical shifts and in the presence of IPP (red) and compound 1a (green) 
at 100:1 compound-to-protein ratio (the spectrum of BFI in free form shown in black). Arrows 
indicate chemical shift perturbations found for compound 1a, but not IPP, which are identical 
to the ones observed in the titration of HMBPP. 
The Intracellular Domain of BTN3A1 Undergoes Conformational Changes after 
Binding to Phosphoantigens. 
Adams group was able to determine the structures of BTN3A1 B30.2 domain in free 
and bound forms with a resolution of 1.4 Å (89). The structures revealed a basic pocket for 
phosphoantigen binding and mutations of key residues from positive to negative completely 
ablated phosphoantigen binding. The phosphoantigen used for crystallization structural 
determination was cHDMAPP, which showed a similar thermodynamic profile as HMBPP 
(Table 8) in our ITC experiments, which is also consistent with their results. 
Surprisingly, the free B30.2 domain and the B30.2-cHDMAPP complex are almost 
identical structurally as the phosphoantigen was not able to induce any noticeable 
conformational changes in BTN3A1 (Figure 41). This leads to a question: what is the molecular 
mechanism connecting the phosphoantigen binding to the downstream signaling then to the 
eventual activation of Vγ9Vδ2 T cells? 
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Figure 41. Structural comparison between free BTN3A1 B30.2 domain (gray, PDB entry: 
4N7I) and B30.2-cHDMAPP complex (green, PDB entry: 4N7U) 
The unobserved structural changes in B30.2 domain may be explained by the BTN3A1 
construct used in the study. Compared to our BFI construct, the B30.2 domain is truncated at 
the N-terminus and lacks the 68-residue juxtamembrane (JM) region. Our 1H-15N HSQC 
titration data indicate the involvement of the 68-residue JM region in interactions with 
phosphoantigens (Figure 37). This evidence indirectly proves the significance of the JM region 
in the probable structural rearrangements of intracellular BTN3A1. As the JM region may be 
the harbor for cellular binding partners such as periplakin (96), biologically and functionally, it 
is reasonable to speculate the JM region can be switched from “inactive” form to “active” form 
upon binding of phosphoantigens. Another possibility is that the JM region interacts with the 
cell membrane, which enables BTN3A1 to have an “inside-out” signaling like integrins. In this 
scenario, the intracellular binding of BTN3A1 to phosphoantigens causes a change in binding 
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affinity of the extracellular domain to its unknown counter-partners. It is plausible since the 
ectodomain of BTN3A1 seems to dimerize in two different modes, IgC-to-IgC and IgV-to-IgC 
(103). 
To further investigate the potential structural changes in intracellular BTN3A1 
especially the JM region, we performed SAXS analysis on BFI in absence and presence of 
HMBPP. Our initial results did suggest changes in the overall shape of BFI. The shape of BFI 
can be viewed as a body part and a head part connected by a short neck region. We suspect 
the body part encompasses the B30.2 domain due to size similarity in comparison to structure 
determined by X-ray. (89). We also believe the JM region forms the head and neck and extends 
to the body part. The most pronounced change in shape upon HMBPP binding occurs in the 
neck region, where a narrowing is observed. In addition, there are other distinctions between 
the free and bound structures, which are difficult to describe at the moment due to the low-
resolution of the models. Overall, the SAXS results are consistent with our hypothesis of 
BTN3A1 intracellular conformational changes and warrant further structural investigations of 
intracellular BTN3A1, especially the JM region. 
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Figure 42. Structures of BFI with (green) and without (gray) HMBPP by SAXS 
Discussion 
During the course of these studies, two groups reported binding of phosphoantigens to 
BTN3A1 via conflicting mechanisms (88, 89). Initially, di Libero and colleagues demonstrated 
extracellular binding whereas a recent paper by Adams clearly showed intracellular binding. 
Our studies are in strong agreement with those from the Adams lab. In addition to the 
calorimetry assay, we also see strong interactions as assessed by NMR spectroscopy. Our 
results also demonstrate for the first time the relative contribution of the prenyl alcohol group 
and/or olefin position is more important that the second phosphate group, because compound 
1a affects the binding of HMBPP to BTN3A1 to a much greater extent than IPP, which lacks 
the alcohol functional group. Additionally, we have compared the effects of different antigen 
binding on the full intracellular domain and the PRY/SPRY domain by NMR. Our results 
indicate that although the binding site for phosphoantigens is localized in PRY/SPRY domain, 
the 68-residue membrane proximal region, preceding PRY/SPRY, also undergoes major 
structural rearrangement upon binding (Figure 37C). These findings clearly promote a model 
in which intracellular binding of phosphoantigens to BTN3A1 induces a conformational change, 
which either propagates across the membrane to the extracellular region or promotes an 
interaction with another intracellular protein thus allowing new transmembrane complex 
formation necessary for recognition by the Vγ9Vδ2 T cell receptor. 
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Research Design and Methods 
Cloning and Purification of BTN3A1 Constructs 
BTN3A1 constructs were purified based on the method that De Libero and colleagues 
(88) used for the IgV domain with some modifications. Amplicons were obtained from THP-1 
cDNA using the following primers in Table 9. 
Construct Forward Primer Reverse Primer 
IgV 
GCT ATC CAT ATG TCA 
GCT CAG TTT TCT GTG 
GCT ATC CTC GAG AAC 
CTT CAG CTC CAC CAG 
BFI 
GCT ATC CAT ATG CAA 
CAG CAG GAG GAA AAA 
GCT ATC CTC GAG CGC 
TGG ACA AAT AGT CAG 
PRY/SPRY 
GCT ATC CAT ATG GCG 
GAT GTG ATT CTG GAT 
GCT ATC CTC GAG CGC 
TGG ACA AAT AGT CAG 
Table 9. Primers used for BTN3A1 constructs 
Each forward primer contained an NdeI site while each reverse primer contained an 
XhoI site. Following amplification and digest, sequences were cloned into the NdeI and XhoI 
sites in pET21b+, resulting in a 6x His-tagged construct. Each construct was validated by 
sequencing using the standard T7 forward and T7 reverse primers. The plasmids were 
transformed into BL21(DE) E. coli. The cells were grown in LB broth until OD600 reached 0.6 
at which point the overexpression was induced by 1 mM IPTG. Cells were lysed by French 
Press and the cell debris was removed by centrifugation at 18,000 rpm at 4 °C. The 
supernatant containing the soluble target protein was collected for further purification. The C-
terminal His-tag fused protein was purified under native conditions with Ni-NTA resin (QIAGEN) 
using the standard protocol followed by a buffer exchange to 50 mM Tris, pH 7.5, 100 mM 
NaCl, 5 mM β-mercaptoethanol (BME) in a Superdex-75 column (GE Healthcare) where all 
three recombinant proteins showed a proper folding in monomeric state. The overexpression 
of the target protein and the purified protein were confirmed by SDS-PAGE and bands of the 
expected mass were observed. 
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ITC Experiments 
Calorimetric measurements of BTN3A1 domains to various compounds were 
performed on a low volume Nano ITC (TA Instruments). All experiments were carried out in a 
buffer of 50 mM Tris, pH 7.5, 100 mM NaCl, 5 mM BME at 25 °C with a stirring speed of 200 
rpm to minimize the precipitation of the protein. Each titration consisted of twenty 2.5-µl 
injections with 300 second time intervals. The concentrations of protein samples were 
determined by UV and the titrant of the compounds were prepared in the same buffer from the 
dilution of 10 mM or 100 mM stock. The concentrations of the protein ranged from 30 μM to 60 
μM. The concentration of protein was examined after each ITC experiment and a good 
solubility (> 85%) of the protein under this condition was shown. The analysis of the data was 
done in NanoAnalyze Software (TA Instruments) suite using an “independent” model. In all 
cases, a stoichiometry of 1 ± 0.1 was revealed. 
15N-HSQC Titration by NMR 
15N-labelled recombinant proteins were overexpressed in M9 medium supplemented 
with 15NH4Cl as the sole nitrogen source. Same purification procedures as described above 
were followed. NMR samples of 100-200 µM were prepared in a buffer of 50 mM Tris, pH 7.5, 
100 mM NaCl, 5 mM BME, 7% D2O, 1 mM DSS as the internal standard. 1H-15N Heteronuclear 
Single Quantum Correlation (HSQC) titration experiments were performed on Varian Inova 
600 MHz spectrometer equipped with inverse-triple resonance cyroprobe at 25 °C. All spectra 
were processed with NMRPipe (104) and analyzed in CcpNmr Analysis software suite (67). 
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Chapter 8 Conclusions 
In summary, the above studies on p52 Shc and BTN3A1 demonstrate how ITC and 
NMR can be utilized to characterize protein interactions. 
Chapter 1 and Chapter 2 serve as a brief overview of the two biophysical techniques. 
Chapter 3 discusses the significance of p52 Shc in MAPK and PI3K/AKT pathways. In 
Chapter 4, we presented a study on phospho-Tyrosine(s) vs. phosphatidylinositol binding in 
p52 Shc-mediated integrin signaling. p52 Shc has been identified as a primary signaling 
partner for the tyrosine(s)-phosphorylated cytoplasmic tails of activated β3 integrins. Inspired 
by our recent structure of the Shc PTB domain in complex with a bi-phosphorylated peptide 
derived from β3 cytoplasmic tail, we have initiated the investigation of Shc interaction with 
phospholipids of the membrane. We are particularly focused on PtdIns and their effects on Shc 
mediated integrin signaling in vitro. Here we present thermodynamic profiles and molecular 
details of the interactions between Shc, integrin, and PtdIns, all of which have been studied by 
ITC and solution NMR methods. A model of p52 Shc interaction with phosphorylated β3 integrin 
cytoplasmic tail at the cytosolic face of the plasma membrane is proposed based on these data. 
Chapter 5 introduces the importance of the Vγ9Vδ2 T cells in human immune system 
and highlights the significance of BTN3A1 in the phosphoantigen-induced Vγ9Vδ2 T cell 
activation. Chapter 6 is a discussion why the extracellular binding of BTN3A1 to 
phosphoantigens is unlikely. In Chapter 7, we demonstrate high affinity interaction between 
phosphoantigens and the intracellular domain of BTN3A1: while the PRY/SPRY (B30.2) 
domain forms the binding pocket, perturbations in the JM region were also observed upon this 
interaction. In addition, our cell-based assay proves a prodrug approach may represent the 
future direction of phosphoantigen development in clinical Vγ9Vδ2 T cell-based 
immunotherapies.  
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